

AAA



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 0 669 829 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
08.08.2001 Bulletin 2001/32

(51) Int Cl.7: C12N 15/19, C12N 15/62,  
A61K 35/28, C07K 14/52,  
A61K 38/19, C12N 15/85,  
C12N 5/10

(21) Application number: 93925071.8

(22) Date of filing: 26.10.1993

(86) International application number:  
PCT/US93/10295

(87) International publication number:  
WO 94/09803 (11.05.1994 Gazette 1994/11)

### (54) ENHANCEMENT OF XENOGRAFT TOLERANCE AND PORCINE CYTOKINES THEREFOR STEIGERUNG DER TRANSPLANTATTOLERANZ DURCH SCHWEIN CYTOKINE AMELIORATION DE LA TOLERANCE AUX XENOGREFFES ET CYTOKINES PORCINES PREVUES A CET EFFET

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

(30) Priority: 27.10.1992 US 967188  
08.10.1993 US 133979

(43) Date of publication of application:  
06.09.1995 Bulletin 1995/36

(73) Proprietor: BIOTRANSPLANT, INC  
Charlestown, MA 02129 (US)

(72) Inventors:

- PONATH, Paul, D.  
Boulder, CO 80301 (US)
- ROSA, Margaret, D.  
Winchester, MA 01890 (US)
- MONROY, Rodney, L.  
Rockport, MA 01966 (US)
- SCHACTER, Bernice, Z.  
Madison, CT 06443 (US)
- HAWLEY, Robert, J.  
Newton, MA 02158 (US)

(74) Representative:  
LOUIS, PÖHLAU, LOHRENTZ & SEGETH  
Postfach 3055  
90014 Nürnberg (DE)

(56) References cited:

- EMBL Database Entry SSCKIT; Accession number L07786; 2 January 1883; ZHANG Z. ET AL.: "Porcine stem cell factor/c-kit ligand: its molecular XP002025285
- Transplantation, Volume 51, No. 4, issued April 1992, GUZZETTA et al., "Induction of Kidney Transplantation Tolerance Across Major Histocompatibility Complex Barriers by Bone Marrow Transplantation in Miniature Swine", pages 862-866, see entire article.
- Bio/Technology, Volume 11, issued February 1993, LAVALLIE et al., "A Thioredoxin Gene Fusion Expression System that Circumvents Inclusion Body Formation in the E. coli Cytoplasm", pages 187-193, see entire article.
- Cell, Volume 47, issued 10 October 1986, YAN et al., "Human IL-3 (Multi-CSF): Identification by Expression Cloning of a Novel Hematopoietic Growth Factor Related to Murine IL-3", pages 3-10, see entire article.
- Cell, Volume 63, issued 05 October 1990, MARTIN et al., "Primary Structure and Functional Expression of Rat and Human Stem Cell Factor DNAs", pages 203-211, see entire article.
- Gene, Volume 105, issued 1991, McINNES et al., "Cloning and Expression of a cDNA Encoding Ovine Granulocyte-Macrophage Colony-Stimulating Factor", pages 275-279, see entire article.

BEST AVAILABLE COPY

EP 0 669 829 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- Z. ZHANG ET AL.: "Porcine stem cell factor/c-kit ligand: Its molecular cloning and localization within the uterus.", BIOLOGY OF REPRODUCTION, , January 1994, vol. 50, no. , pages 95 to 102

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

**Description**

[0001] This application is a continuation-in-part of U.S. serial no. 07/967,188, filed October 27, 1992.

5 [0002] This invention relates to a method for enhancing xenogeneic transplantation of porcine tissue or organs using porcine bone marrow and porcine cytokines, and to recombinant DNA molecules for expression of porcine cytokines and fusion proteins containing them. The porcine cytokines are useful for improving engraftment, stabilization and proliferation of tissues, particularly bone marrow cells, in xenogeneic transplantation.

**BACKGROUND OF THE INVENTION**

10 [0003] Organ procurement currently poses one of the major problems in organ transplantation, as the number of patients requiring transplants far exceeds the number of organs available. Xenotransplantation may provide a solution to this problem. Phylogenetically, non-human primates are the most closely related species to humans and might therefore represent the first choice as donors. In 1969, Reetsma et al. achieved the first successful kidney human 15 xenograft from a chimpanzee (Reetsma, K. et al., 1964, Ann. Surg. 160:384). However, the potential utilization of primate donors is limited by insufficient numbers, legal and ethical considerations, and the potential for transmitting dangerous viral diseases. Swine represent one of the few large animal species in which breeding characteristics make 20 genetic experiments possible, making it possible to develop MHC homozygous lines of miniature swine. Miniature swine can be maintained at maximum adult weights of 90 to 136 kg (200 to 300 lbs) and are anatomically and physiologically close to humans. Therefore the organs of miniature swine seem appropriate for use as xenografts for human beings of all ages.

[0004] Tolerance to self major histocompatibility (MHC) antigens occurs during T cell maturation in the thymus (McDuffie et al., J. Immunol. 141:1840, 1988). Exposure of the immune system to MHC antigens during ontogeny can cause the immune system to lose reactivity to those antigens, thus leaving the animal specifically tolerant into adult 25 life (Billingham et al., 1953, Nature 172:603). Transplantation immunologists have sought means of inducing tolerance in adult animals by production of lymphohematopoietic chimeras. The induction of tolerance across MHC barriers in adult mice by whole body irradiation (WBI) and bone marrow transplantation (BMT) has been studied extensively in murine models (Hayfield et al., 1983, Transplant. 36:183; Mayumi et al., 1989, J. Exp. Med. 169:213; Sykes et al., 1988, Immunol. Today 9:23).

30 [0005] The use of MHC mismatched BMT as a means of inducing tolerance to organ grafts can be accompanied by several major disadvantages: the preparative regimen involves lethal irradiation, with its inherent risks and toxicities; clinical applicability is limited by the fact that most potential recipients do not have an appropriate MHC-matched donor, and BMT across MHC barriers causes severe graft-vs-host-disease (GVHD). Removing the T lymphocytes in allogeneic bone marrow inocula (Rodt et al., 1971, Eur. J. Immunol. 4:25) to prevent GVHD is associated with increased rates of 35 engraftment failure (Martin et al., 1988, Bone Marrow Transplant. 3:445; O'Reilly et al., 1985, Transplant. Proc. 17:455; Soderling et al., 1985, J. Immunol., 135:941). While these drawbacks are generally considered acceptable for the treatment of otherwise lethal malignant diseases, they would severely limit the application of MHC mismatched BMT as a preparative regimen for organ transplantation, in which non-specific immunosuppressive agents, while not without major complications, are effective.

40 [0006] Use of a relatively non-toxic, non-myeloablative preparative regimen for bone marrow engraftment and specific transplantation tolerance has been applied to the concordant rat to mouse species combination (Sharabi, Y. et al., 1990, J. Exp. Med. 172:195-202). The treatment involved administration of monoclonal antibodies to eliminate mature T cell subsets (CD4 and CD8) as well as NK cells (NK1.1). These monoclonal antibodies permitted engraftment of 45 xenogeneic bone marrow after only a sub-lethal (300 rads) dose of WBI and a local dose of 700 rads thymic irradiation. The resulting lymphoid reconstitution was superior to that of previously mixed xenogeneic chimeras prepared by lethal irradiation and reconstitution with mixtures of T cell-depleted syngeneic and xenogeneic bone marrow (Sharabi, Y., et al., 1990, J. Exp. Med. 172:195-202; Ildstad, et al., 1984, Nature 307:168-170) as recipients did not suffer toxic effects from the preparative regimen. In addition, attempts have been made to lengthen the survival of skin allografts in primates and man by intravenously administering a polyclonal preparation of horse anti-human antithymocyte globulin (ATG). 50 The ATG was injected simultaneously with and on days immediately following grafting (Cosimi, A.B. et al., 1970, Surgery. 68:54-61).

55 [0007] It has been recognized that the use of swine organs for xenogeneic transplantation to humans is facilitated by inducing tolerance (i.e., reducing the severity of and/or eliminating any immunological response to the transplant) to swine tissue using swine bone marrow. The swine bone marrow cells (BMC) can be transplanted to the recipient's marrow and engraft there. Engraftment, as used herein, refers to implantation or transplantation of porcine BMCs into a xenogeneic recipient or host such that the porcine BMCs proliferate, differentiate and function as bone marrow in the recipient. The porcine bone marrow can be introduced before transplantation of the swine organ, contemporaneously with the organ transplantation, or both. In this context, contemporaneously or substantially contemporaneously

contemplates introduction during the same operative procedure or as part of preoperative preparation.

[0008] In addition Martin F.H. et. al., Cell 1990, Vol.63, pages 203-211 report about the cloning of rat stem cell factors using PCR techniques. The cDNA sequence reported does not have significant similarity to any sequence in the GenBank or EMBL data bases. It is also shown in this document that rat SCF is active on human bone marrow in combination with EPO and, furthermore possesses a high cross-species activity on human cells. However no disclosure relating to a xenogenic environment is contained in said report.

[0009] McInnes, C.J. and Haig, D. M., Gene 1991, Vol.105, no.2, pages 275-279, report about the cloning of ovine granulocyte-macrophage colony-stimulating factor (GM-CSF) using the polymerase chain reaction. Transient expression of recombinant ovine GM-CSF is also reported about and its biological activity was investigated in a bone-marrow colony-forming assay. Ovine GM-CSF was found to promote the formation of granulocyte-macrophage-colonies as well as eosinophil, neutrophil and monocyte/macrophage colonies, an activity indicated to be characteristic of GM-CSF in other species. It was also found that recombinant human GM-CSF have no proliferate effect on ovine bone-marrow cells.

[0010] Yang, Y.-C. et al., Cell 1986, Vol. 47, pages 3-10, report the cloning of a haematopoietic growth factor related to murine Interleukin 3. Although certain activities of GM-CSF, for instance, were disclosed, no indication towards the promotion of growth of e.g. bone-marrow cells in a xenogeneic environment is given in this report.

[0011] In accordance with the present invention, it has been recognized by the inventors that it would be highly desirable to promote the engraftment of the porcine bone marrow and that cytokines which have an effect on marrow engraftment are highly species specific in their effect. In accordance with the invention, the inventors recognized the deficiency that porcine cytokines effective to promote porcine bone marrow engraftment had not been identified, isolated, characterized or produced, such as by recombinant techniques and that such was highly desirable for use in the above and other applications.

[0012] In particular the present invention relates to a polynucleotide comprising a nucleotide sequence which codes for a polypeptide according to any of claims 1 to 10, an expression vector according to any of claims 11 to 15 and 19 to 21, isolated bone-marrow cells according of any of claims 16 to 18 and the polynucleotide according to claim 22 as well as a polypeptide according to any of claims 23 to 29 and the use of one or more polypeptides according to any of claims 23 to 28 as claimed in claims 29 and 30.

[0013] Accordingly, other principal aspects of the invention are porcine cytokines that preferentially enhance the proliferation and engraftment of porcine bone marrow cells in the presence of bone marrow cells of other species, DNA sequences therefor and DNA molecules for expression of these porcine cytokines. More particularly, the invention provides porcine chimeric enhancement factors ("CHEFs") that are porcine analogs of interleukin-1 (hereinafter "CHEF-1"), granulocyte-macrophage colony stimulating factor (hereinafter "CHEF-2") and stem cell factor (hereinafter "CHEF-3") as well as combinations of these novel porcine cytokines with each other and with other porcine cytokines, such as porcine leukemia inhibitory factor (hereinafter "porcine LIF"). The porcine cytokines of the invention are contemplated to encompass the protein whether purified from native origin, expressed by recombinant methodologies or chemically synthesized.

[0014] As will be explained in more detail below, the porcine bone marrow that is preferentially stimulated by the porcine cytokines in the recipient prepares the recipient for the tissue or organ transplantation by inducing tolerance at both the B-cell and T-cell levels. Preferably, the bone marrow cells include immature cells (e.g., undifferentiated hematopoietic stem cells; these cells can be separated out of the bone marrow prior to administration), or a complex bone marrow sample including such cells can be used.

[0015] Preferred embodiments include those in which: swine of the same immunological profile are the donor of both the tissue or organ to be transplanted and the bone marrow; the recipient mammal is a primate, preferably a human; and the swine is a partially or completely inbred strain, e.g., a miniature swine. In a preferred embodiment of the method of use, the recipient is irradiated with low dose radiation prior to introducing the bone marrow, preferably with radiation of more than 100 rads and less than 400 rads.

[0016] Figure 1 graphically illustrates the extent of colony formation induced by mLKM, pLKM and their combination in various bone marrow cell populations of monkey, pig and mixed ratios of monkey/pig cells using LCM that was the spun, filtered supernatant of peripheral blood lymphocytes stimulated continuously for 7 days with PHA, based on the experiments reported in Example 1.

[0017] Figure 2 graphically illustrates the dose dependence and exceptional species specificity of porcine bone marrow cell proliferation. Tritiated thymidine uptake (0-45,000 cpm) was measured using porcine, monkey and human LCM over a range of concentrations (V/V) of LCM in IMDM medium (% CM) in the experiments reported in Example 1.

[0018] Figure 3 shows the nucleic acid sequence and derived amino acid sequence of the CHEF-3 coding region, as described in Examples 2, 3 and 4. Expression in mammalian cells begins with the first methionine, but signal peptide cleavage is predicted to yield a protein secreted from mammalian cells beginning with amino acid 26 (glutamine, indicated in bold).

[0019] Figure 4 shows an SDS-PAGE analysis of lysates of E. coli bearing plasmid pMDR1069, which encodes a

GST-CHEF-3 fusion, as described in Example 3. Samples prior to induction with IPTG (PRE) and following a 5 hour induction with IPTG (POST) were analyzed with protein molecule weight markers indicated (in kDa). The induced GST-CHEF-3 fusion protein is indicated by the arrow.

5 [0020] Figure 5 shows the proliferative response of pig BMC to the stimulus provided by supernatant from COS cells transfected with the pCHEF-3 construct, as described in Example 4. The material from the mock transfected cells did not stimulate proliferation.

[0021] Figure 6 shows a Northern blot of total RNA from porcine peripheral blood mononuclear cells hybridized under low stringency to an antisense RNA probe from human GM-CSF cDNA clone huGM#23 as described in Example 5.

10 [0022] Figure 7 shows the results of assay of conditioned media, harvested from cells used for RNA analysis as shown in Figure 6, for porcine bone marrow proliferation activity, as further described in Example 5.

15 [0023] Figure 8 shows the nucleotide sequence and derived amino acid sequence of CHEF-2 determined by sequencing the cDNA insert of clone INC1-1A and subclone pCHEF-2.pcd. Sequences derived from linkers used in construction of the cDNA library are underlined. Expression in mammalian cells starts at the first ATG (position 23, bold), beginning a typical mammalian signal peptide sequence, and continues to a TAA termination codon (position 462, bold), as described in Examples 5 and 6.

[0024] Figure 9 shows an SDS-PAGE analysis of lysates of *E. coli* bearing plasmid pDA110, which encodes thioredoxin-CHEF-2 fusion protein, as described in Example 6. Samples prior to induction with IPTG (PRE) and following a 5 hour (POST 5h) or 16 hour (POST 16h) induction with IPTG (POST) were analyzed with protein molecule weight markers indicated (in kDa). The induced thioredoxin-CHEF-2 fusion protein is indicated by the arrow.

20 [0025] Figure 10 shows the detection of GM-CSF proliferative activity in COS cell supernatants of COS cells transfected with a plasmid containing the CHEF-2 expression plasmid pCHEF-2EXP.pcd (pGM-CSF) or with pcDNA I/Amp alone (Mock-CM), as described in example 7.

[0026] Figure 11 diagrammatically illustrates the steps for the cloning of CHEF-1, described in Example 8. A restriction map of genomic DNA isolated is shown below in a scale in kilobases (S: Sfi I; X: Xba I; Z: Xho I). Line figures at the bottom represent phage isolated in the two screenings of the porcine genomic library. Regions encoding the porcine GM-CSF (CHEF-2) and porcine IL-3 (CHEF-1) genes are indicated.

25 [0027] Figure 12 shows the nucleotide sequence and derived amino acid sequence of pCHEF-1.pcd1, as described in Examples 8, 9 and 10. The first ATG (bold) starts at position 24, beginning a typical mammalian signal peptide, and continues to a TAA termination codon beginning at position 456 (bold). Underlined sequences indicate PCR primers ILP-F (positions 1-15, underlined) and ILP-R (positions 740-760, underlined) used to isolated the CHEF-1 cDNA by PCR.

30 [0028] Figure 13 shows an SDS-PAGE analysis of lysates prepared from *E. coli* bearing plasmid pEXIL-4, which encodes GST-CHEF-1 fusion protein, as described in Example 9. Samples prior to induction with IPTG (PRE) and following a 3.5 hour (POST) induction with IPTG (POST) were analyzed with protein molecule weight markers indicated (in kDa). The induced GST-CHEF-1 fusion protein is indicated by the arrow.

35 [0029] Figure 14, illustrating results from Example 10, shows the proliferative response to COS cell supernatants containing CHEF-1 in a 3 day bioassay. An approximate 10-fold increase in cellular activity was detected with a dose of 0.078% conditioned medium, but with increasing doses of CHEF-1 further increases were not observed.

40 [0030] Figure 15, illustrating results from Example 10 shows the proliferative response to COS cell supernatants containing CHEF-1 in a 7 day bioassay. The results from the 7 day proliferation show a similar approximately 10-fold increase with only 0.078% conditioned media but additional cellular activity was detected with increasing doses of CHEF-1, to approximately 40-fold with >1.25% CHEF-1 containing COS cell supernatant.

[0031] Figures 16-23 illustrate results described in Example 11.

45 [0032] Figure 16 graphically illustrates the results of the bone marrow cellular proliferation assay. Stimulation of pBMC by LIF (n) or a combination of CHEF-3 and LIF (20% CHEF; o) is depicted in this Figure. Proliferation of porcine bone marrow cells is increased 2-3 fold by the stimulation with CHEF-3 and porcine LIF as compared to LIF alone.

[0033] Figure 17 graphically illustrates the unique combined activities of CHEF-3 and LIF in a colony formation assay, where colony formation is assessed either in the presence of LIF alone (n) or with combinations of either 10% (o) or 20% CHEF-3 (u).

50 [0034] Figures 18 and 19. Effect of LIF and either primary allo- or xeno-stromal cells on cellular and progenitor cell development of pBMC after 1 week in culture. The effect of LIF on pig bone marrow cellularity (Figure 18) and progenitor cell content (Figure 19) at the end of 7 days of culture on either pig stromal cells (n) or primate stromal cells (o) or no stromal cells (=). The results are mean values of 3 separate experiments.

55 [0035] Figures 20 and 21. Effect of LIF, CHEF 3 and either primary xeno or allo-stromal cells on cellularity (Figures 20A and 20B) and progenitor cell development (Figures 21A and 21B) after 1 week in culture. Cultures were established. The variable is the addition of either LIF [50ng/ml], CHEF-3[20%COS cell supernatant] or the combination of both to standard LTBMC media. At the end of 7 days, all cells from 2 wells were harvested, cell number was determined and an aliquot of cells was plated in a colony forming assay.

[0036] Figures 22A - 22D. A comparative long term effect of continuous versus two weeks of added exogenous LIF to cellular and progenitor cell development in xeno-LTBMC. Primary primate stromal cells were prepared as previously described and seeded with 500,000 pig BMC. Cells were plated in either standard LTBMC media or media supplemented with LIF, [50ng/ml]. All cells from 2 wells were harvested at weekly intervals to document the development of the cultures. In panels A and B, the effect of continuous LIF (o) on cellularity (Figure 22A) and progenitor cell development (Figure 22B) was compared to media (n) alone. In panels C and D, LIF (o) was maintained in the cultures for only the first two weeks. After the second week, the media was replaced with standard LTBMC media. This was compared to media alone [n] for the entire culture period.

[0037] Figure 23. A comparison of the long term effect of continuous CHEF-3 or CHEF-3 + LIF on the cellular and progenitor cell development in xeno-LTBMC. LTBMC were established and set up as previously described. In these experiments, the effects standard LTBMC media (u) were compared to CHEF-3 (20% COS cell supernatant; n) or CHEF-3 [20%] and LIF [50ng/ml] (o). Documentation of the development of the LTBMC was as previously described.

[0038] A principal aspect of the invention relates to enhancing tolerance of a porcine transplant in a xenogeneic recipient, particularly a human, by administering to the recipient a tolerance-inducing amount of porcine bone marrow cells and at least one porcine cytokine in an amount sufficient to enhance the proliferation and engraftment of the porcine bone marrow cells therein. Porcine bone marrow cells and cytokines can be introduced to the xenogeneic recipient before and/or contemporaneously with introduction of the porcine transplant to the xenogeneic recipient. The porcine bone marrow cells are preferably administered systemically, e.g., intravenously.

[0039] The porcine cytokines can be selected to be those which preferentially enhance: activation of other porcine cytokines; proliferation of porcine marrow progenitor cells; proliferation of porcine marrow hematopoietic cells; proliferation of marrow stem (particularly hematopoietic stem) cells; or proliferation of porcine granulocyte and macrophage cells.

[0040] This can be accomplished, for example, by bathing the porcine bone marrow cells in a composition comprising at least one porcine cytokine in a physiologically acceptable liquid prior to their administration to the recipient. Also, the porcine cytokine(s) can be systemically administered to the recipient, e.g., by intravenous injection or infusion, in admixture with the porcine bone marrow cells or as a separately pharmaceutical preparation. When formulated as a separate preparation, the cytokine(s) are administered slightly before or substantially contemporaneously (as defined above) with the porcine bone marrow cells.

[0041] In another principal aspect, the invention relates to a porcine cytokine that is substantially free of other porcine proteins and preferentially enhances the proliferation and engraftment of porcine bone marrow cells in the presence of bone marrow cells of other species. Embodiments of this aspect include cytokine(s) isolated from native porcine tissue sources such as porcine tissue extracts, cultured cells and the like such that it is rendered substantially free of other proteins or macromolecules of porcine origin. Other embodiments include cytokine(s) prepared by recombinant techniques, including those using expression vectors in prokaryotic or eukaryotic host cells to form an expression system. The expression vectors can contain structural coding sequences for the cytokine that are fragments of cDNA prepared to be complementary to mRNA isolated from porcine cells or tissue extracts. Other embodiments include fusion protein products, of such expression systems, that exhibit similar porcine cytokine bone marrow proliferation and engraftment activities. Further embodiments include such proteins that are chemically synthesized as well as any proteins or fragments thereof that are substantially homologous.

[0042] "Substantially homologous," which can refer both to nucleic acid and amino acid sequences, means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between reference and subject sequences. For purposes of the present invention, sequences having greater than 90 percent homology, equivalent biological activity, and equivalent expression characteristics are considered substantially homologous. For purposes of determining homology, truncation of the mature sequence should be disregarded. Sequences having lesser degrees of homology, comparable bioactivity, and equivalent expression characteristics are considered equivalents.

[0043] Definitions of certain additional terms used herein will provide guidance as to the contemplated metes and bounds of such terms. "Recombinant," as used herein, means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems. "rCHEF" means recombinant porcine cytokine chimeric enhancement factor "Microbial" refers to recombinant proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a porcine protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Protein expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycosylation modifications; protein expressed in yeast will have a glycosylation pattern different from that expressed in mammalian cells.

[0044] "DNA segment" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery

of the segment and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where they do not interfere with manipulation or expression of the coding regions. "Nucleotide sequence" typically refers to a heteropolymer of deoxyribonucleotides. Generally, DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant "transcriptional unit," comprising regulatory elements derived from a microbial or viral operon.

5 [0045] "Recombinant expression vector" refers to a plasmid or phage comprising a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include

10 an N-terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

15 [0046] Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and the *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to induce transcription of a downstream structural sequence. Such

20 promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

25 [0047] Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a porcine cytokine together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *30 Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may, also be employed as a matter of choice.

35 [0048] As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM 1 (Promega, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Additional details regarding the use of a bacterial expression system to produce recombinant CHEF-3 protein as part of a fusion protein, with glutathione-S-transferase, are provided in Example 3, below.

40 [0049] Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is derepressed by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

45 [0050] Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation sites, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to 50 provide the required nontranscribed genetic elements. Additional details regarding the use of a mammalian high expression vectors to produce recombinant CHEF protein are provided in the working examples.

55 [0051] Recombinant protein produced in bacterial culture is usually isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of CHEF proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Use of an expression system which expresses a CHEF protein as a secreted protein greatly simplifies purification.

[0052] "Recombinant expression system" means a substantially homogeneous monoculture of suitable host micro-organisms, for example, bacteria such as *E. coli* or yeast such as *S. cerevisiae*, which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid. Generally, cells constituting the system are the progeny of a single ancestral transformant. Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed.

[0053] Mature porcine cytokines can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce porcine cytokines using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Maniatis, Molecular Cloning: A Laboratory Manual, (Cold Spring Harbor, N.Y., 1985).

[0054] One preferred embodiment of this aspect relates to porcine cytokine Chimeric Enhancement Factor-3 (CHEF-3) that has now been identified, isolated and prepared. The protein and DNA sequences of CHEF-3 and one possible coding sequence therefor are shown in the attached drawings and the method by which these were ascertained are described in the examples. The CHEF-3 porcine cytokine(s) of this aspect preferentially enhances the proliferation of porcine marrow progenitor cells, more particularly porcine marrow hematopoietic cells, stem cells and ideally porcine hematopoietic stem cells. The porcine cytokine referred to as "CHEF-3" herein has the polypeptide sequence shown as SEQ ID NO:4.

[0055] Another preferred embodiment of this aspect relates to porcine cytokine Chimeric Enhancement Factors (CHEFs), particularly CHEF-2 that has now been identified, isolated and prepared. The protein and DNA sequences of CHEF-2 and one possible coding sequence therefor are shown in the attached drawings and the method by which these were ascertained are described in the examples. The porcine cytokine(s) of this aspect preferentially enhances the proliferation of porcine granulocyte and macrophage cells. The porcine cytokine referred to as "CHEF-2" herein has the polypeptide sequence shown as SEQ ID NO:11.

[0056] Another preferred embodiment of this aspect relates to porcine cytokine Chimeric Enhancement Factors (CHEFs), particularly CHEF-1 that has now been identified, isolated and prepared. The protein and DNA sequences of CHEF-1 and one possible coding sequence therefor are shown in the attached drawings and the method by which these were ascertained are described in the examples. The porcine cytokine(s) of this aspect preferentially enhances the proliferation of porcine granulocyte and macrophage cells. The porcine cytokine referred to as "CHEF-1" herein has the polypeptide sequence shown as SEQ ID NO:21.

[0057] Another preferred aspect of the invention relates to fusion proteins containing CHEF-3 and/or CHEF-2 and/or CHEF-1 activity and activity of at least one additional protein, particularly hematopoietic porcine cytokine activity, but also expression facilitating proteins, e.g. glutathione-S-transferase as in Example 2 that can be cleaved, e.g. by thrombin, for isolation of the CHEF protein.

[0058] Another aspect of the invention relates to combinations of CHEF-3 and/or CHEF-2 and/or CHEF-1 with other porcine cytokines when they are also substantially free of other porcine source proteins or other porcine native source macromolecules except for the CHEF-3 and/or CHEF-2 and/or CHEF-1 of the invention.

[0059] In another aspect, the invention provides an expression vector capable of expressing both a CHEF of the invention, e.g. CHEF-3, CHEF-2 or CHEF-1, and another porcine cytokine, preferably one with which it synergistically interacts, particularly to enhance hematopoietic differentiation, and xenogeneic porcine bone marrow engraftment. Preferred examples include the combination of CHEF-3 or CHEF-1 with porcine leukemia inhibitory factor (LIF).

[0060] In another aspect of the invention, the efficiency of transduction of porcine cells, particularly bone marrow and hematopoietic cells, is significantly enhanced when transduction is effected in a medium containing the vector to be introduced as well as one or more of the porcine cytokines of the invention. In general, porcine bone marrow cells are cultured in the presence of 20 ng/ml CHEF-1 and 100 ng/ml CHEF-3, with or without additional cytokines. By analogy to transduction experiments performed with other species, an increase in cellular proliferation of up to 200 fold may be expected, with significantly elevated efficiency of stem cell transduction and replication prior to transfer to the recipient.

[0061] Another aspect of the invention provides transfected porcine cells or tissue modified to express elevated amounts of the cytokine(s) of the invention. For example, the bone marrow stromal cells can be transfected or transduced with vectors expressing CHEF-1, a protein unique to the swine but essential for survival and growth of porcine bone marrow. The modified stromal cells can then be co-transplanted with other porcine bone marrow cells and improve engraftment.

[0062] In another aspect, the porcine cytokines enhance the viability and maintenance in culture of totipotent or pluripotent stem cells, including primordial germ cells as well as inner cell mass-derived cells. These stem cells can be modified and selected in culture for expression of genes of interest, including but not limited to genes encoding transplantation antigens. Such stem cells, which require the porcine cytokines for growth in culture as undifferentiated cells, can differentiate into any somatic or germline cell type when reassociated with a developing host embryo at the

preimplantation stage. Some animals generated by that route from stem cells modified to express genes of interest will produce gametes carrying the modification and can be bred to generate lines appropriately expressing the modification. Alternatively, modified stem cells can be used to generate transgenic animals using the nuclear transfer procedure, where stem cell nuclei are introduced into a non-fertilized, enucleated oocyte and give rise to genetically uniform offspring carrying the modification. By analogy to the mouse system, we anticipate that in the pig at least some of the porcine cytokines (e.g. CHEF-3 and CHEF-3/LIF combinations) serve physiological functions which include germ cell development. As in the mouse, the porcine homolog of Stem Cell Factor, CHEF-3, is likely to be a critical component for culturing embryonic germ cells derived from genital ridges of early postimplantation embryos (days 23 to 30 post estrus). CHEF-3 can be provided for this purpose as a soluble factor in concentrations of 1ng/ml to 1 ug/ml or as a membrane bound constituent of feeder cells. The end result is the capacity to produce transgenic strains of swine that express a novel phenotype, such as a trait or protein product, i.e., a modified immunological profile of a particular organ intended for xenogeneic transplant donation that renders it immunologically more similar to the homologous recipient organ's immunological profile.

[0063] The porcine cytokines of the invention are also useful as "lead compounds" that can be modified or whose structure/function interactions with receptors or other molecules can be studied to synthesize or screen for low molecular weight mimetics or antagonists. Such modifications could include those designed to increase the activity of the compound on its target cells, increase the pharmacological half-life, provide enhanced species specificity, or reduce the antigenicity of the compound.

[0064] Another principal aspect of this invention is a method of inducing tolerance in a xenogeneic transplantation host, such as a human recipient, of a porcine organ by introducing the porcine CHEF cytokines, combinations of them or combinations of them with other porcine cytokines *per se* or in combination with porcine bone marrow or hematopoietic cells, whether fully differentiated or as expanded cultures of progenitor cells, to the intended recipient prior to introduction of the porcine transplant organ.

[0065] In the case of xenogeneic transplantation of tissue or organs, the donor of the implant and the animal that supplies the tolerance-inducing bone marrow is preferably of the same immunological profile. For example, it is preferable to derive implant tissue from a colony of donors that is highly inbred. Implanted tissue may consist of organs such as liver, kidney, heart; body parts such as bone or skeletal matrix; tissue such as skin, intestines, endocrine glands; or progenitor stem cells of various types. Primarily contemplated for such transplants are the solid, formed and more highly specialized organs such as the liver, kidney, heart or lung.

[0066] Another aspect of the invention provides for the stimulation of bone marrow proliferation in swine bone marrow donors by administering one or more of the porcine cytokines of the invention or compositions containing one or more of them to the marrow donor swine prior to recovery of bone marrow therefrom. For example, it may be preferable for engraftment and the induction of tolerance to have a bone marrow harvest enriched in a specific progenitor cell population which is an improved transplantation product. This product would enhance engraftment and the induction of tolerance. It is also contemplated that the harvested bone marrow can be cultured *ex vivo* in the presence of various CHEFs to generate a bone marrow population which is an improved transplantation product. This product would enhance engraftment and the induction of tolerance.

[0067] Another aspect of the invention relates to a method of enhancing the proliferation of porcine bone marrow cells in a xenogeneic recipient which comprises exposing said cells to the porcine cytokine of the invention. A related aspect provides a method for enhancing engraftment of porcine bone marrow cells, in a recipient mammal by, prior to or simultaneous with transplantation of the tissue, introducing the porcine cytokine or mixtures thereof with other substantially pure porcine cytokines in accordance with the invention into the recipient. Modes of introducing and related information regarding dose ranges and administration routes, regimens, vehicles and the like are discussed below. The cytokine(s) can preferably be administered systemically by intravenous infusion.

[0068] Bone marrow cells (BMC) of the donor injected into the recipient home to appropriate sites of the recipient and grow contiguously with remaining host cells and proliferate, forming a chimeric lymphohematopoietic population. By this process, newly forming B cells (and the antibodies they produce) are exposed to donor antigens, so that the transplant will be recognized as self. Tolerance to the donor is also observed at the T cell level in animals in which BMC engraftment has been achieved. When an organ graft is placed in such a recipient after bone marrow chimerism has been induced, the graft is accepted by both the humoral and cellular arms of the immune system. The use of a porcine cytokine in accordance with the present invention preferentially stimulates the porcine bone marrow cells to provide engraftment thereof in the recipient.

[0069] The method of introducing bone marrow cells may be altered, particularly by (1) increasing the time interval between injecting BMC and implanting the tissue; (2) increasing or decreasing the amount of BMC injected; (3) varying the number of BMC injections; (4) varying the method of delivery of BMC; or (5) varying the source of BMC. Although BMC derived from the tissue donor is preferable, BMC may be obtained from other individuals or species, or from genetically-engineered inbred donor strains, or from *in vitro* cell culture.

[0070] In another aspect of the invention, it has been recognized that the novel porcine cytokines have additional

utility in the prevention or treatment of various infections or diseases to which swine population are susceptible. Examples of such maladies include those for which the pig is especially reliant on granulocyte activity for recovery (e.g. African Swine Fever) or those which can lead to generalized immunosuppression (e.g. Hog cholera, Pseudorabies, Swine Influenza).

5 [0071] In another principal aspect of the invention, the CHEF proteins, fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal, monoclonal, chimeric, single chain, Fab fragments, or an Fab expression library. Various procedures known in the art may be used for the production of polyclonal antibodies. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples  
10 include the hybridoma technique (Kohler and Milstein, 1975, *Nature* 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce CHEF-specific single chain antibodies. The antibodies can be used in methods relating to the  
15 localization and activity of the protein sequences of the invention, e.g., for imaging these proteins, measuring levels thereof in appropriate physiological samples and the like.

20 [0072] The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of the porcine cytokine, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

25 [0073] In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ameliorate any pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

30 [0074] The therapeutics of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

35 [0075] Modes of administration of the porcine cytokine include but are not limited to intravenous, intramuscular and subcutaneous routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection and may be administered together with other biologically active agents. Administration is preferably systemic, e.g., by intravenous infusion separately or in combination (preferably admixture) with porcine bone marrow cells.

40 [0076] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

45 [0077] The porcine cytokine(s) is used in an amount effective to promote engraftment of porcine bone marrow in the recipient. In general, such amount is at least 5 $\mu$ g/kg body weight and most generally need not be more than 500 $\mu$ g/kg. Preferably, it is at least about 20 $\mu$ g/kg and usually need not be more than about 100  $\mu$ g/kg. The cytokine will be administered for a period of at least 7 days but generally not to exceed 30 days, with a typical therapeutic treatment period of 7 to 14 days. The cytokine will preferably be administered either intravenously or subcutaneously, one to three times per day, and will be adjusted to meet optimal efficacy and pharmacological dosing.

50 [0078] The following examples illustrate the invention in various of its aspects without being a limitation on its scope. The examples set forth below are listed as follows:

EX 1 - SPECIES SPECIFIC HEMATOPOIETY OF PORCINE CYTOKINES

EX 2 - ISOLATION AND SEQUENCING OF THE PORCINE CHEF-3 cDNA GENE

EX 3 - GST-CHEF-3 FUSION PROTEIN EXPRESSED FROM *E. COLI*

55 EX 4 - EXPRESSION OF CHEF-3 IN COS CELLS AND DETECTION USING A PORCINE BONE MARROW ASSAY

EX 5 - ISOLATION AND SEQUENCING OF THE PORCINE CHEF-2 cDNA GENE

EX 6 - THIOREDOXIN-CHEF-2 FUSION PROTEIN EXPRESSED FROM *E. COLI*

EX 7 - EXPRESSION OF CHEF-2 IN COS CELLS AND DETECTION USING A PORCINE BONE MARROW ASSAY

EX 8 - ISOLATION AND SEQUENCING OF THE PORCINE CHEF-1 cDNA GENE

EX 9 - GST-CHEF-1 FUSION PROTEIN EXPRESSED FROM *E. COLI*

5 EX 10 - EXPRESSION OF CHEF-1 IN COS CELLS AND DETECTION USING A PORCINE BONE MARROW ASSAY

EX 11 - SYNERGISTIC COMBINATION OF CHEF-3 WITH PORCINE LIF

**EXAMPLE 1**

10

**Species Specific Hematopoicity of Porcine Cytokines**

[0079] Sources for Peripheral Blood: Human volunteers were informed of the intent of the study and signed an informed consent for blood donation. The procurement of peripheral blood from animal donors (pig and cynomolgus monkeys [*Macaca fascicularis*]) was in accordance with approved protocols for the care and use of laboratory animals.

15 [0080] Isolation of Peripheral Blood Mononuclear Cells: Peripheral blood was obtained from donors by venapuncture into heparinized Vacutainer® tubes (Becton Dickinson, Rutherford, NJ). Peripheral blood was diluted with an equal volume of phosphate buffered saline and layered over Histopaque (specific gravity 1.077 gm/l, Sigma, St. Louis, MO) and centrifuged at 2000 rpm for 15 minutes. Low density mononuclear cells (PBMNC) were isolated at the media-

20 Histopaque interface and washed twice in Iscove's Modified Dulbecco's Media (IMDM, GIBCO BRL, Gaithersburg, MD) containing 20% fetal bovine serum (FBS, GIBCO BRL, Gaithersburg, MD), 1% L-Glutamine (GIBCO BRL Gaithersburg, MD), 1% Penicillin-streptomycin (solution of each antibiotic at 10,000 units/ml, GIBCO BRL Gaithersburg, MD) and  $1 \times 10^{-4}$  M 2-mercaptoethanol (Sigma, St. Louis, MO).

25 [0081] Preparation of Lymphocyte Conditioned Media (LCM): Isolated PBMNC were adjusted to a cell concentration of  $1 \times 10^6$ /ml in Iscove's Modified Dulbecco's Media (IMDM, GIBCO BRL, Gaithersburg, MD) containing 20% fetal bovine serum (FBS, GIBCO BRL, Gaithersburg, MD), 1% 1-Glutamine (GIBCO BRL Gaithersburg, MD), 1% Penicillin-streptomycin (solution of each antibiotic at 10,000 units/ml, GIBCO BRL Gaithersburg, MD) and  $1 \times 10^{-4}$  M 2-mercaptoethanol. Phytohemagglutinin (PHA) (GIBCO BRL, Gaithersburg, MD) was added to the cells at a concentration of 1 ml/100 ml media containing PBMNC. PBMNC, 100 ml, were placed into tissue culture flasks (162 cm<sup>2</sup>, Costar, Cambridge, MA) and incubated for 7 days at 37°C, in a 5% CO<sub>2</sub> atmosphere. At the end of 7 days, the supernatant was harvested after pelleting the cells by centrifugation (2000 rpm, 10 minutes) and sterile filtered through a 0.22 mm filter (Costar, Cambridge, MA).

30 [0082] Bone Marrow Cells: Bone marrow was obtained from either pig or monkey bones. Monkey femurs were purchased from the Texas Primate Center (Hazelton Research Products, Alice, TX). Bones were harvested from the donor, shipped on wet ice overnight and bone marrow cells were isolated the following day. Pig bone marrow cells were isolated from ribs of pig kidney donors (Transplantation Biology Research Center, Massachusetts General Hospital, Charlestown, MA) on the same day as procurement. Under sterile conditions, bones are cut into smaller pieces and marrow is scraped and washed from the bone using a solution of Dulbecco's phosphate buffered saline (GIBCO BRL, Gaithersburg, MD) containing 10% citrate phosphate dextrose solution (Sigma, St. Louis, MO) and gentamycin 100 mg/ml (GIBCO-BRL, Gaithersburg, MD). Bone marrow cells (BMC) were washed several times with the phosphate buffered saline solution (used above) and resuspended in RPMI-1640 media (GIBCO BRL, Gaithersburg, MD) containing 10% FBS and gentamycin at a cell concentration of  $2 \times 10^6$ /ml in tissue culture flasks (15 ml per 75 cm<sup>2</sup> flask). BMC were incubated overnight at 37°C, 5% CO<sub>2</sub> after which time nonadherent cells were harvested from the flasks and washed with RPMI-1640 media. These cells were used in the clonogenic assay.

35 [0083] Clonogenic Assay: A titration of monkey BMC versus pig BMC was maintained where a combined total of pig and monkey BMC were plated at a concentration of 48-50,000 cells per ml of assay media. Four combinations were used in this study:  $50 \times 10^3$  monkey::  $0 \times 10^3$  pig;  $32 \times 10^3$  monkey::  $16 \times 10^3$  pig;  $16 \times 10^3$  monkey::  $32 \times 10^3$  pig; and  $0 \times 10^3$  monkey::  $50 \times 10^3$  pig. In addition, to validate linearity of colony formation, monkey and pig BMC were plated separately at concentrations of 16 and  $32 \times 10^3$ /ml. Media used in these assays was an IMDM based media with 30% FBS, either 5% pig LCM or 5% monkey LCM or both LCM at 5%, and 1.15% methylcellulose (Terry Fox Laboratories, Vancouver, BC). Control cultures did not contain any source of LCM. Cultures were plated in duplicate at 1 ml volumes in 35 mm plates (Nunc, Naperville, IL). Cultures were incubated for 7 days at 37°C, 5% CO<sub>2</sub> and colonies (composed of 50 cells or greater) were counted as a colony.

40 [0084] Proliferation Assay: A proliferation assay was used to compare the response of pig BMC to cytokines from different species. Pig BMC ( $2.5 \times 10^4$ ) were plated in each well of a 96 well "u" bottom tissue culture plate containing 200 ml of media. The media base was serum free, AIM-V media (GIBCO BRL, Gaithersburg, MD) to this was added 0, 1, 3, 5, 7, or 10% LCM from either pig, monkey or human. Triplicate evaluations were performed for each LCM concentration. Cultures were incubated for 6 days at 37°C, 5% CO<sub>2</sub>; after which time, 1 mCi of tritiated thymidine [<sup>3</sup>H-

45

50

55

Tdr, (Amersham Corp., Arlington Heights, IL) was added and cultures were incubated for an additional 16 hours. Culture plates were harvested onto a glass fiber filter on the seventh day using a TOMTEC harvester (Tomtec Inc., Orange, CT). Radioactive samples were determined using a Betaplate reader (Wallac Inc., Gaithersburg, MD) and results expressed as counts per minute.

5 [0085] The results of porcine specific molecules providing specific growth advantage to pig bone marrow cells in a mixture of monkey and pig bone marrow is illustrated in Figure 1. In this culture system, pig cells responded only to the pig specific conditioned media and not to the monkey conditioned media. Monkey cells did respond to pig conditioned media but only 10% of what was observed in the presence of monkey conditioned media. Therefore, the preferential growth of the pig cells was accomplished by using pig specific factors.

10 [0086] Dose dependence and exceptional species specificity of porcine bone marrow cell proliferation was also demonstrated as shown in Figure 2. Tritiated thymidine (T\*) uptake by porcine bone marrow cells was measured when exposed to porcine, monkey and human LCM over a range of concentrations (V/V) of LCM in IMDM medium (%CM).

## EXAMPLE 2

### Isolation and Sequencing of the Porcine CHEF-3 cDNA Gene

15 [0087] Endothelial Cell Isolation and Culture: Endothelial cells were derived from miniature swine aorta by scraping the luminal surface of the blood vessel as described by Ryan et al. (Tissue and Cell, 12:619-635 1980). The cells were resuspended in M199 medium supplemented with 20% fetal bovine serum (GIBCO BRL, Gaithersburg, MD) and gentamycin and plated in 25 cm<sup>2</sup> tissue culture flasks pre-coated with fibronectin (5 µg/cm<sup>2</sup>) and laminin (1 µg/cm<sup>2</sup>). Endothelial cell growth supplement (Collaborative Research, Bedford, MA) at 150 µg/ml was added only at the beginning of the culture. The cultures were maintained by changing one half of the media every 2-3 days. The subculture was passaged by treating the cells with 0.25% trypsin-EDTA (Gibco BRL) for 2 minutes when the monolayer was confluent.

20 [0088] Cultures consisted of homogeneous cells with typical endothelial cell morphology. The cells were subcultured four times before they were used for messenger RNA isolation.

25 [0089] Oligonucleotides: The following oligonucleotides were purchased from Oligos Etc., (Wilsonville, OR):

30 1. dL-1 (SEQ ID NO 1): 5'-GCGCTGCCTT TCCTTATGAA G. dL-1 is a 5' end primer including 15 nucleotides of 5' untranslated region and the first two codons of the signal peptide for human Stem Cell Factor (Martin, F.H. et. al. Cell, 63:203-211 (1990)).

35 2. FC-1 (SEQ ID NO 2): 5'-TTAGGCTTTC CTATTACTGC TACT. FC-1 is a 3' end primer (reverse complement of transcribed sequence) with the first three nucleotides comprising an artificial stop codon and the remaining 21 nucleotides complementary to the sequence encoding amino acids 173-179 of secreted form of murine Stem Cell Factor (Anderson, D.H. et. al. Cell, 63:235-243 (1990)).

40 [0090] RNA Isolation and RNA PCR: RNA was extracted from pig aortic endothelial cells by lysis in 4M guanidine isothiocyanate and ultracentrifugation through 5.7M cesium chloride. Total RNA (1 µg) was reverse transcribed using the RNA PCR kit purchased from Perkin-Elmer Cetus (Norwalk, CT). Annealing and reverse transcriptase extension conditions were 25°C for 5 minutes, 37°C for 5 minutes, 42°C for 25 minutes. Subsequent amplification was performed with the addition of the dL-1 5' oligonucleotide primer and cycle conditions of 94°C for 1 minute, 50°C for 1 minute, 72°C for 1 minute with a final extension at 72°C for 7 minutes. The fragment was gel purified on 1% agarose and subcloned directly into the Eco RV site of pBluescript KS II+ (Stratagene, La Jolla, CA) to create pCHEF-3.

45 [0091] The sequence of the CHEF-3 cDNA gene was determined by sequencing multiple subclones of the dL-1/Fc-1 PCR product by the dideoxy chain termination method using the Sequenase™ T7 polymerase kit (US Biochemical, Cleveland, OH). All sequences were in agreement with that determined for the insert portion of pCHEF-3.

50 [0092] DNA and protein sequence comparisons were made using the GeneWorks sequence analysis package (Intelligenetics, Mountain View, CA) and sequences from the following sources:

55 1) Human Stem Cell Factor: Martin, F.H. et. al. Cell, 63:203-211 (1990).  
GenBank accession number M59964.

2) Murine Stem Cell Factor: Anderson, D.H. et. al. Cell, 63:235-243 (1990).  
GenBank accession number M38436.

3) Rat Stem Cell Factor: Martin, F.H. et. al. Cell, 63:203-211 (1990).  
GenBank accession number M59966.

[0093] Figure 3 shows the nucleotide (SEQ ID NO: 3) and predicted amino acid (SEQ ID NO: 4) sequences of the CHEF-3 coding region. The insert of pCHEF-3 is comprised of the sequence of dL-1 (nucleotides 1-21) joined to au-

thentic porcine sequence (nucleotides 22-609) joined to the reverse complement of FC-1 sequence (nucleotides 610-633). Protein expression in mammalian cells should initiate with the methionine encoded by nucleotides 1-3 and terminate with an alanine encoded by nucleotides 613-615. Based on studies with stem cell factor from other species, mammalian cells are predicted to secrete a protein beginning with a glutamine encoded by nucleotides 76-78 (bold) derived from the above by signal peptide cleavage. In comparable regions, the CHEF-3 cDNA gene has nucleic acid homologies of 91%, 87%, and 86% with Stem Cell Factor from human, mouse, and rat species respectively.. All are single nucleotide substitution except for an insertion of 3 nucleotides in the pig CHEF-3 gene. At the amino acid level, CHEF-3 is 83% similar to rat and human Stem Cell Factor , while CHEF-3 and mouse Stem Cell Factor are 80% similar.

10 **EXAMPLE 3**

**GST -CHEF3 Fusion Protein Expressed from E. coli**

15 [0093] This example describes a method for construction of the vector pMDR1069 (a glutathione-S-transferase gene fusion protein expression vector).

20 [0094] pCHEF-3 was modified in order to insert an EcoRI site following the translation termination codon at the 3' end of the CHEF-3 sequence. pCHEF-3 was cleaved with HindIII, the terminii were "filled-in" using the Klenow fragment of DNA polymerase I (Boehringer Mannheim Biochemicals, Indianapolis, IN). EcoRI linkers (pCGGAATTCCG [SEQ ID NO: 5] New England BioLabs, Inc., Beverly, MA) were ligated to the HindIII cleaved pCHEF-3. Prior to transformation of E. coli JM101 HindIII was added to the ligation reaction in order to linearize any recircularized pCHEF-3. Ampicillin resistant colonies were screened for the presence of a 650 bp EcoRI fragment. The resulting vector is described as pMDR1068. pMDR1068 was cleaved using PstI and EcoRI and the approximately 650 bp fragment was isolated by LMA (low melting-temperature agarose).

25 [0095] pGEX-2T was purchased from Pharmacia LKB Biotechnology, Piscataway, NJ 08854. The plasmid pGEX-2T is designed for inducible high-level expression of genes as a fusion with *Schistosoma japonicum* glutathione-S-transferase (GST). Cleavage of the 26 kDa GST domain from the fusion protein is facilitated by the presence of a recognition sequence for thrombin immediately upstream from the multiple cloning site. pGEX-2T was cleaved with EcoRI, de-phosphorylated and cleaved with BamHI. The 4.9 Kb fragment was isolated by LMA.

30 [0096] Oligonucleotides CHE02 and CHE03 were synthesized using an Applied Biosystems Inc. (Foster City, CA) oligonucleotide synthesizer.

**CHE02 (SEQ ID NO: 6): 5'-GATCACAAAGG GATCTGCA**

35 **CHE03 (SEQ ID NO: 7): 5'-GATCCCTTGT**

40 [0097] The DNA fragments and oligonucleotides were ligated and the ligation mix was used to transform E. coli JM101. Ampicillin resistant colonies were screened for the presence of a 1500 bp PstI fragment. The resulting plasmid is described as pMDR1069

45 [0098] Expression of the GST-CHEF-3 Fusion Protein from pMDR1069: A single colony of pMDR1069 in E. coli JM101 was grown overnight in Terrific Broth (TB). Sambrook, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press) containing 50 mg/ml Ampicillin. 0.5 ml of the overnight culture was added to 50 ml TB + 50 mg/ml Ampicillin) and grown at 37°C with vigorous shaking (350 r.p.m.) until the culture reached an optical density of 1, measured at 600 nm. An aliquot was removed as the pre-induction sample and then isopropyl-b-D-thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM. Aliquots were removed at 1, 3, 5 and 16 hrs post-induction. The cells were centrifuged, resuspended in reducing buffer for protein gels and boiled for 10 min prior to analysis by 10% polyacrylamide-SDS gel electrophoresis. The gel was stained using Coomassie Blue. Cells containing the plasmid pGEX-2T were analysed as the negative control. The presence of a protein band at approximately 46 kDa indicates the induction of the GST-CHEF-3 fusion protein.

50 [0099] Figure 4 shows an SDS-PAGE analysis of lysates prepared as above. Samples prior to induction with IPTG (PRE) and following a 5 hour induction with IPTG (POST) were analyzed with protein molecule weight markers indicated (in kDa). The induced GST-CHEF-3 fusion protein is indicated by the arrow.

**EXAMPLE 4****Expression of CHEF-3 in COS cells and detection using a porcine bone marrow assay**

5 [0100] Construction of pCHEF-3EXP.pcDNA1/Amp was purchased from Invitrogen Corporation (San Diego, CA). pcDNA1/Amp facilitates high level transient expression of recombinant proteins in eukaryotic cells. The plasmid was cleaved with EcoRI and XbaI and dephosphorylated using calf alkaline phosphatase.

10 The vector fragment was purified from LMA. The DNA fragments were ligated and the ligation mix was used to transform *E. coli* JM101. Ampicillin resistant colonies were screened for the presence of 570 bp fragment. The resulting plasmid, pCHEF-3EXP.pcDNA1/Amp, contains the entire sequence of pCHEF-3 (SEQ ID NO:3) insert shown in Figure 3.

[0101] Expression of CHEF-3 from transiently transfected COS cells: COS7 cells were obtained from the ATCC (Rockville, MD) and are grown in DMEM + 10% fetal calf serum (DMEM-10). The COS7 cells were transfected using 15 2 mg/ml DNA and 15 mg/ml LIPOFECTIN Reagent (Gibco BRL) in Opti-MEM serum-free medium (Gibco BRL) for 5 hrs, after which time the medium was replaced with DMEM-10. Cells were allowed to grow for 72 hrs and the supernatant medium was collected, filtered and assayed for the presence of CHEF-3.

[0102] Detection of CHEF-3 in Transfected COS Cell Supernatant: Pig BMC were plated in 96 well "U" bottom tissue culture plates at a concentration of  $2.8 \times 10^4$  cells per well. The media base was Modified Eagles media (MEM-199, 20 GIBCO BRL, Gaithersburg, MD) containing 13% FBS; this media was made 5% (V/V) with concentrated (12-fold) supernatants from either mock-transfected COS cells or either pCHEF-3EXP.pcDNA1/Amp transfected COS cells. Cultures were incubated for 5 days at 37°C, 5% CO<sub>2</sub>; each well was pulsed with one microcurie <sup>3</sup>H-Tdr and incubated for an additional 16 hours. Culture plates were harvested onto a glass fiber filter using a TOMTEC harvester (Tomtec Inc., Orange, CT). Radioactive content of the samples was determined using a Betaplate reader (Wallac Inc., Gaithersburg, MD) and results expressed as counts per minute.

[0103] Figure 5 shows the proliferative response of pig bone marrow cells in the presence of no additional agent (control), COS supernatants from cells transfected with pcDNA1/Amp (mock COS) or COS supernatant from cells transfected with pCHEF-3EXP.pcDNA1/Amp (CHEF COS) assayed as described above.

**EXAMPLE 5****Isolation and Sequencing of the Porcine CHEF-2 cDNA Gene**

35 [0104] RNA isolation from peripheral blood lymphocytes: Peripheral blood mononuclear cells from human volunteers and miniswine were isolated as described in Example 1. Total RNA was isolated according to the method of Chergwin (Biochemistry, 18:5294, 1979). Poly A+ RNA was isolated using poly-U Sephadex chromatography (GIBCO BRL, Gaithersburg, MD) according to the manufacturer's instructions.

[0105] Human GM-CSF cDNA isolation: Total RNA from human peripheral blood mononuclear cells (PBMCs) cultured in the presence of 1% phytohemagglutinin (PHA; GIBCO BRL) for 72 hours (1 µg) was reverse transcribed and 40 used in a polymerase chain reaction (PCR) as described in Example 2. The following primers were used:

- 1) Reverse transcription primer: XN-2 (SEQ ID NO: 14) 5'-TGGTTCCCAG CAGTCAAAGG G. XN-2 is the reverse complement of nucleotides 416-436 of the ovine GM-CSF cDNA gene (McInnes, C.J. and Haig, D.M. Gene 105: 275-279 (1991). GenBank accession number Z18291).
- 45 2) Forward PCR primer: XW3 (SEQ ID NO: 8), 5'-TTGGGGCACTG TGGCCTGCAG C. XW3 is derived from nucleotides 57-77 of the human GM-CSF cDNA gene (Lee, F. et. al. Proc. Natl. Acad. Sci. U.S.A. 82:4360-4368 (1985). GenBank accession number M14743.).
- 3) Reverse PCR primer: XW4 (SEQ ID NO: 9), 5'-ACAGGAAGTT TCCGGGGTTG G. XW4 is the reverse complement of nucleotides 351-371 of the human GM-CSF cDNA gene (Lee, F. et. al. Proc. Natl. Acad. Sci. U.S.A. 82: 4360-4368 (1985). GenBank accession number M14743.).

50 The resulting 315 bp fragment was subcloned into the EcoRV site of pBluescript KS+ (Stratagene, LaJolla, CA) using standard methods, generating plasmid phuGM#23. Randomly primed probes (T7 Quickprime; Pharmacia, Piscataway, NJ) were prepared using the cloned insert isolated from a low melting temperature agarose gel. T7 RNA polymerase antisense transcripts were made using the Riboprobe transcription kit (Promega, Madison, WI).

[0106] Porcine lymphocyte conditioned media and lymphocyte RNA analysis: Porcine (miniswine) PBMC were cultured essentially as described in Example 1. Cells were treated with either 1% phytohemagglutinin (PHA), PHA and 5ng/ml phorbol 12-myristate 13-acetate (PHA+PMA; Sigma, St. Louis, MO), or no additional agents (Control) for 24

hours. On day 1 (immediately following treatment) cells were washed and split into 4 aliquots of fresh media without additional treatment. RNA was isolated from 1 aliquot of cells, and the corresponding conditioned media collected, on days 2-5.

5 [0107] Filtered supernatants were assayed for the presence of proliferation stimulating activity as follows. Pig bone marrow cells, at 25,000 cells per well, were placed in a 96 well tissue culture plate. Each well contained 200  $\mu$ l of media (Iscove's Modified Dulbecco's Media, 10% fetal bovine serum, and 10% (v/v) conditioned media). Cultures were plated in triplicate and incubated at 37°C for 7 days. On day 6, each well was pulsed with 20  $\mu$ l of media containing  $^3$ H-Tdr (1 microcurie per well). Cells were harvested using a Harvester (Tomtec) and incorporated  $^3$ H-Tdr was detected using a Beta plate reader. Values are means of the triplicate wells.

10 [0108] RNA was fractionated on agarose-formaldehyde gels as described (T. Maniatis, ed., Molecular Cloning: A Laboratory Manual) and transferred to nylon membranes (GeneScreen; DuPont NEN) according to the manufacturer's instructions. The RNA blot was hybridized with  $5 \times 10^5$  cpm/ml human GM-CSF antisense RNA probe in 5 x SSPE (1 x SSPE is 0.15M NaCl, 0.01M NaH<sub>2</sub>PO<sub>4</sub>, 0.001M EDTA), 50% formamide buffer at 42° C and washed in 2 x SSPE, 0.1% sodium dodecyl sulfate at 62° C.

15 [0109] cDNA library construction and screening: Poly A+ RNA was isolated from porcine peripheral blood mononuclear cells 5 days after a 16 hour treatment with PHA as described above. Doublestranded cDNA (dscDNA) with Eco RI adapters was prepared using the Timesaver cDNA synthesis kit (Pharmacia) according to the manufacturer's instructions. The dscDNA was ligated into the lambda replacement vector lgt-10 (Stratagene, LaJolla, CA) and packaged using the Packagene kit (Promega). The resulting phage were amplified on E. coli strain NM514. For screening, 1 X

20  $10^5$  amplified phage were plated on 150 mm plates using strain C600 Hfl (Promega). Six (6) duplicate filter sets, containing phage amplified from  $3 \times 10^5$  independent clones, were hybridized to randomly primed phuGM#23 plasmid insert in 5 x SSPE buffer at 50° C and washed in 2 x SSPE buffer at 50° C. Putative positives from the first screen were subjected to a second round of screening as above. DNA from clone INC1-1A, selected from the above, was prepared from liquid lysate culture for sequencing.

25 [0110] Sequencing of CHEF-2 cDNA clones: DNA from clone INC1-1A was sequenced from either end of the insert using lgt-10 forward and reverse sequencing primers and the fmol Sequencing Kit (Promega). After confirming substantial homology to GM-CSF sequences from other species, the insert was removed from INC1-1A with Not I and subcloned into the Not I site of plasmid pcDNA I Amp (InVitrogen, San Diego, CA). One subclone, having the proper 5'-3' orientation relative to the vector CMV promoter, was designated pCHEF-2.pcd. The insert from pCHEF-2.pcd was sequenced completely on both strands using the Sequenase sequencing kit (US Biochemical, Cleveland, OH) as described in Example 2.

30 [0111] DNA and protein sequence comparisons were made using the GeneWorks sequence analysis package (Intelligenetics, Mountain View, CA) and sequences from the following sources:

35 1) Human GM-CSF: Lee, F. et. al. Proc. Natl. Acad. Sci. U.S.A. 82:4360-4368 (1985). GenBank accession number M14743.  
 2) Murine GM-CSF: Miyatake, S. et. al. EMBO J. 4:2561-2568 (1985). GenBank accession number K01850.  
 3) Ovine GM-CSF: McInnes, C.J. and Haig, D.M. Gene 105:275-279 (1991). GenBank accession number Z18291.  
 4) Bovine GM-CSF: Maliszewski, C.R. et. al. Mol. Immunol. 25:843-850 (1988).

40 [0112] As shown in Figure 6, Northern blots of total RNA from porcine peripheral blood mononuclear cells were hybridized under low stringency to an antisense RNA probe from human GM-CSF cDNA clone phuGM#23. Cells were treated for 16 hours with PHA or PHA and PMA, washed, then harvested 2-5 days following initiation of treatment. A homologous transcript of approximately 800 nt (arrow) is induced by PHA treatment on days 4 and 5. A number of constitutively expressed transcripts cross hybridize to the probe under low stringency conditions.

45 [0113] As shown in Figure 7, conditioned media, harvested from cells used for RNA analysis as shown in Figure 6, was assayed for porcine bone marrow proliferation activity. A significant increase in activity appears in media from PHA treated cells on day 5, following an induction of a transcript homologous to human GM-CSF on day 4.

50 [0114] Figure 8 shows the nucleotide sequence (SEQ ID NO: 10) and derived amino acid sequence (SEQ ID NO: 11) of the CHEF-2 cDNA gene determined by sequencing clone 11NC1-1A and subclone pCHEF-2.pcd. Expression in mammalian cells starts with the first ATG (position 23, bold), beginning a typical mammalian signal peptide, and continues to a TAA termination codon (position 455, bold). Nucleotides 1-7 (underlined) and 789-798 (underlined) are derived from the Not I/Eco RI adaptors used in construction of the cDNA library. Within the coding regions, CHEF-2 has nucleic acid homologies of 70%, 88%, 81% and 81% with GM-CSF from murine, ovine, human and bovine species respectively. Inclusive of the signal peptides, CHEF-2 has amino acid identities of 54% with murine, 80% with ovine, and 72% with human and bovine GM-CSF.

**EXAMPLE 6****Thioredoxin-CHEF-2 Fusion Protein Expressed from *E. coli***

5 [0115] This example describes a method for construction of the vector pDA110 (a thioredoxin gene fusion protein expression vector).

[0116] Isolation of the mature CHEF-2 sequence: The 381 base pairs that code for the 127 amino acids corresponding to mature CHEF-2 (Figure 8, nucleotides 81-461) were cloned using PCR technology. Two oligonucleotides were synthesized for amplification of the gene. Their sequences are shown below:

10

DA14 (sense primer; SEQ ID NO: 12): 5'-CGACGGTACC GGCTCCCACC  
CGCCCCACCC

15

DA15 (antisense primer; SEQ ID NO: 13): 5'-AGGATCTAGA  
GGATCCTCAT CACTTTTGA CTGGCCCCCA

20

[0117] The oligonucleotides were designed such that the 5' end of the amplified fragment would contain a complete Kpn I site (GGTACC) and the 3' end a complete Xba I site(TCTAGA) downstream of the stop codon of the CHEF-2 gene. The Kpn I site was designed for the in-frame ligation of the CHEF-2 fragment to the 3' end of thioredoxin sequence.

25 [0118] Clone 1NC1-1A contains the CHEF-2 cDNA. DNA isolated from this clone was amplified (Perkin Elmer DNA Thermal Cycler Model 480) in a 50  $\mu$ l reaction containing 200  $\mu$ M each dNTP, 0.5  $\mu$ M each primer, 1.5 mM MgCl<sub>2</sub>, 10 mM Tris (pH 8.3), 50 mM KCl, 8% dimethyl sulfoxide, and 0.25 units AmpliTaq DNA polymerase. The reaction was cycled for 0.5 min at 94°C, 1 min ramp to 55°C, 0.5 min at 55°C, 0.5 min ramp to 72°C, 0.5 min at 72°C, 1 min ramp to 94°C for 35 cycles. The PCR products were analyzed on a 10% polyacrylamide gel. The major product band was about 400 bp, which is in good agreement with the expected size of 414 bp. Following the manufacturer's protocol, the DNA was purified using Magic PCR Preps (Promega, Madison, WI). The entire sample was digested first with Kpn I, then with Xba I. The Kpn I/Xba I fragment containing CHEF-2 was purified from the smaller fragments (<10 bp) by again, use of Magic PCR Preps.

30 [0119] Plasmid pTRXFUS (LaVallie et. al. Bio/Technology 11:187-193, 1993) was obtained from Genetics Institute (Cambridge, MA). pTRXFUS DNA was isolated using the Magic Maxi prep kit (Promega, Madison, WI) according to manufacturer's instructions. An aliquot of DNA (4  $\mu$ g) was first digested with Kpn I, then digested with Xba I. Since only a <20 bp fragment is removed from the vector if both restriction enzymes successfully cut, the DNA was subsequently treated with alkaline phosphatase (calf intestinal). The 3580 bp Kpn I/Xba I vector fragment was then purified on a 0.8% agarose gel. The vector fragment and the PCR fragment were ligated and transformed into competent *E. coli* strain G1698 (La Vallie et al., Bio/Technology 11: 187-193, 1993). Putative clones were screened by Hinc II restriction digest analysis. The resulting plasmid containing the gene encoding the thioredoxin-GM-CSF fusion protein is defined as plasmid, pDA110.

35 [0120] Expression of thioredoxin-CHEF-2: A single colony of *E. coli* G1698 (pDA110) was grown overnight at 23°C in 2 mls modified M9CAA media, as described in La Vallie et al. containing 100  $\mu$ g/ml ampicillin. The overnight culture was diluted (1:50) in 10 mls of fresh modified M9CAA containing 100  $\mu$ g/ml ampicillin and was grown at 23°C for two hours. One ml of culture was removed as the pre-induction sample and tryptophan (final concentration of .49 mM) was added to induce expression of thioredoxin-CHEF-2. After 18 hrs, one ml of culture was centrifuged. The pre- and post-induced cells were resuspended in SDS/reducing buffer and both were analyzed on a 12% SDS polyacrylamide gel. Plasmid pTRXFUS was used as a positive control for expression. The gel was stained with Coomassie blue and a new protein band at about 27.3 kDa was observed in the post-induced but not pre-induced sample. The size of this new protein band corresponds to the expected size of the thioredoxin-CHEF-2 fusion protein.

40 [0121] Figure 9 shows an SDS-PAGE analysis of lysates prepared as above. Samples prior to induction with IPTG (PRE) and following a 5 hour (POST 5h) or 16 hour (POST 16h) induction with IPTG (POST) were analyzed with protein molecule weight markers indicated (in kDa). The induced thioredoxin-CHEF-2 fusion protein is indicated by the arrow.

55

**EXAMPLE 7****Expression of CHEF-2 in COS Cells and Detection using a Porcine Bone Marrow Assay**

5 [0122] Construction of pCHEF-2EXP.pcDNA1, a eukaryotic expression vector: pCHEF-2.pcDNA1 was digested at a unique Xba I site within the CHEF-2 insert region (nucleotide 574 of Figure 8) and at a unique Xba I site within the pcDNA I/Amp polylinker region downstream of the Not I insertion site. The protruding ends were blunted with Klenow fragment and the DNA recircularized with T4 DNA ligase. Clone pCHEF-2EXP.pcDNA1 was isolated from *E. coli* transformants of the above DNA and shown by DNA sequencing to differ from pCHEF-2.pcDNA1 by the deletion of CHEF-2 sequences 3' to nucleotide 574 of Figure 8. As this region contains multiple repeats of the sequence ATTAA, previously associated with instability of eukaryotic mRNA molecules, the deletion should permit higher level accumulation of CHEF-2 RNA in COS cells. As nucleotide 480 is 3' to the translational stop codon of CHEF-2, there is no alteration of the expected amino acid sequence shown in Figure 8.

10 [0123] Expression of CHEF-2 from transiently transfected COS cells: CHEF-2 was expressed by transient expression of COS cells as described for CHEF-3 in Example 4.

15 [0124] Detection of GM-CSF Proliferative Activity in COS Cell Supernatants: Pig bone marrow cells (BMC), obtained from pig donor 10758, were harvested aseptically from the femurs, washed in phosphate buffered saline solution, and decanted to remove bone particles. BMC were subsequently separated by continuous-flow centrifugal elutriation using a rotor speed of 2040 rpm and increasing flow rates of 50 and 70 ml/min to elute cells with increasing densities and 20 size. Fractions collected at these flow rates were number 1 and 2. After fraction 2 was collected, both the rotor and fluid flow was stopped, causing the cells remaining in the chamber to pellet. These were harvested from the chamber and represented fraction 3 cells which were used for the proliferation assay.

25 [0125] Fractionated pig bone marrow cells (25,000 cells per well) in Iscove's Modified Dulbecco's Media and 10% fetal bovine serum were added to 96 well microtiter plates to which increasing concentrations of COS cell supernatants were added adjusting the final volume to 200  $\mu$ l/well. Cells were incubated at 37° C for 3 days; on day 2, cells were pulsed with  $^3$ H-Tdr (1 microcurie per well) and wells were harvested 24 hours later. Counts were determined on a Beta Plate reader and expressed as a mean value of 3 wells.

30 [0126] Figure 10 shows the detection of GM-CSF proliferative activity in COS cell supernatants of COS cells transfected with the CHEF-2 expression plasmid pCHEF-2EXP.pcDNA1 (pGM-CSF) or with pcDNA I/Amp alone (Mock-CM).

**EXAMPLE 8****Isolation and Sequencing of the Porcine CHEF-1 cDNA Gene**

35 [0127] Isolation of a genomic clone containing the porcine IL-3 (CHEF-1) gene: A genomic library was constructed in the vector Igem-12 (Promega, Madison, WI) using a Sau 3AI partial digest of miniswine (genotype a/a) peripheral blood mononuclear cell DNA. The library was screened with the cDNA insert of clone pCHEF-2.pcDNA1 (Example 5) to isolate 3 overlapping clones containing at least a portion of the porcine genomic sequence for GM-CSF (Figure 11, clones IS1-2, IS4-1 and IS4-2). The orientation of the clones with respect to the direction of transcription of the CHEF-2 gene was determined by hybridizing Southern blots of phage restriction digests with oligonucleotide probes specific for exons 1 (XN1; (SEQ ID NO:24): 5'-AGGATGTGGC TGCAGAACCT G) or exon 4 (C2X4; (SEQ ID NO:15): ACATCT-GCCA TTTCCCTGC C) of the CHEF-2 gene. Sequences upstream of the CHEF-2 gene (a 1.7 kb Xba I fragment from phage IS4-2; coordinates 23-25 of Figure 11) were used to rescreen the genomic library. Overlapping clones were isolated and restriction mapped. One clone, IS1E-3, was found to contain sequences from 6 through 22 kb upstream of the CHEF-2 promoter. This clone hybridized oligonucleotide probe OL-2 (SEQ ID NO: 16; 5'-CTATGGAGGT TC-CATGTCAG ATAAAG) the sequence of which is conserved among the promoter regions of primate, ovine and rodent species. The clone also hybridized to oligonucleotide probe ILX5 (SEQ ID NO: 17; 5'-ATGTTCAATT GTACCTC) the sequence of which is conserved among the 3' untranslated regions of the same species. Genomic DNA sequence was obtained using the same two primers, and this sequence used to design oligonucleotides ILP-F (SEQ ID NO: 18; 5'-AGACAGGATC CATCGTACCG) and ILP-R (SEQ ID NO: 19; 5'-CTCATTCAAG AGGAGCAGGC) containing sequences from the presumptive 5' and 3' untranslated regions of the CHEF-1 gene, based upon the location of sequences homologous to OL-2 and ILX5 relative to the transcriptional start and polyadenylation sites of the IL-3 gene in other species.

50 [0128] Isolation of a cDNA encoding CHEF-1: Primers ILP-F and ILP-R were used to generate a PCR product of approximately 800 bp from oligo dT primed cDNA derived from poly A+ RNA from pig peripheral blood mononuclear cells 4 days after treatment with PHA, prepared as described in Example 5. This product was digested with Bam HI (which cuts within the ILP-F sequence) and cloned into the Bam HI/Eco RV site of pcDNA I/Amp. One clone was designated pCHEF-1.pcDNA1 and sequenced.

[0129] Sequencing of the CHEF-1 gene: Dideoxy sequencing was performed on PCR derived cDNA clone pCHEF-1.pcd1 and the exonic regions of C1G-2, an Eco RI subclone of IS1E-3 containing the CHEF-1 genomic gene (coordinates 29-35 of Figure 11). Genomic sequence was obtained for all protein coding exon regions, and cDNA sequence was obtained along the entire length of the pCHEF-1.pcd1 insert. Together, this sequence comprised both strands of the CHEF-1 protein coding region in its entirety. Genomic and cDNA sequences were in complete agreement throughout the protein coding region.

[0130] DNA and protein sequence comparisons were made using the GeneWorks sequence analysis package (Intelligenetics, Mountain View, CA) and sequences from the following sources:

- 10 1) Human IL-3: Yang, Y.-C. et. al. *Cell* 47:3-10 (1986). GenBank accession number M14743.
- 2) Murine IL-3: Fung, M.C. et. al. *Nature* 307:233-237 (1984). GenBank accession number K01850.
- 3) Ovine IL-3: McInnes, C.J. et. al. Unpublished. GenBank accession number Z18291.
- 4) Gibbon IL-3: Yang, Y.-C. et. al. *Cell* 47:3-10 (1986). GenBank accession number M14744.

[0131] Figure 11 diagrammatically presents the CHEF-1 cloning steps. A restriction map of genomic DNA isolated is shown below a scale in kilobases (S: Sfi I; X: Xba I; Z: Xho I). Line figures at the bottom represent phage isolated in the two screenings of the porcine genomic library. Regions hybridizing to GM-CSF (CHEF-2) and IL-3 (CHEF-1) oligonucleotide probes are indicated.

[0132] Figure 12 shows the nucleotide sequence (SEQ ID NO: 20) and derived amino acid sequence (SEQ ID NO: 21) of pCHEF-1.pcd1. The first ATG (bold) heads an open reading frame starting at nucleotide 24, beginning with a typical mammalian signal peptide, and continuing to a TAA termination codon beginning at nucleotide 456 (bold). Underlined sequences are derived from PCR primers ILP-F (nucleotides 1-15, underlined) and the reverse complement of ILP-R (nucleotides 740-760, underlined) used to isolate the CHEF-1 cDNA by PCR. Within the coding regions of the genes, CHEF-1 has nucleic acid homologies of 66%, 47%, 47% and 52% with the IL-3 genes of ovine, human, murine and gibbon species respectively. Inclusive of the signal peptides, CHEF-1 has amino acid identities of 46% with ovine, 34% with human, 26% with murine, and 33% with gibbon IL-3.

#### **EXAMPLE 9**

##### **GST-CHEF-1 Fusion Protein Expressed from *E. coli***

[0133] This example describes a method for construction of the vector pEXIL-4 for the expression of soluble CHEF-1 in *E. coli*. Using the method of von Heijne (Nucleic Acids Research 14:4683-4690, 1986), the putative signal peptide cleavage site was determined to precede Met<sub>1</sub> of Figure 12. The portion of the CHEF-1 cDNA gene encoding the mature (mammalian secreted form) is 363 nucleotides (Figure 12, nucleotides 93-455) and encodes a 13.8 kDa protein.

[0134] Isolation of the mature CHEF-1 sequence by PCR: The following oligonucleotides were synthesized to amplify the 363 nucleotides of mature CHEF-1:

[0135] FE2Chf1: (SEQ ID NO: 22) 5' GGGGAATTCA TATGCCTACC ACAACACTC. FE2Chf1 is a sense PCR primer that includes the first 18 nucleotides of mature CHEF-1 (underlined nucleotides). The Met<sub>1</sub> (ATG) codon is contained within an Nde I site (CATATG). In addition, upstream of the Met<sub>1</sub> is an Eco RI site (GAATTC).

[0136] REChf1: (SEQ ID NO:23) 5' CCCAAGCTTG GATCCTATTAGGGCTCTGTG ATCATGGG. REChf2 is an antisense PCR primer that includes tandem stop codons (TAA TGA) and the last 18 nucleotides of mature CHEF-1. Downstream of the stop codons are Bam HI (GGATCC) and Hind III (AAGCTT) sites.

[0137] Primers FE2Chf1 and REChf1 were used to generate a PCR product of approximately 390 bp from pCHEF-1.pcd1 DNA, which contains the CHEF-1 cDNA cloned into the eukaryotic expression vector, pcDNA1/AMP. DNA was amplified (Perkin Elmer DNA Thermal Cycler Model 480) in a 50  $\mu$ l reaction containing 200  $\mu$ M each dNTP, 0.5  $\mu$ M each primer, 1.5 mM MgCl<sub>2</sub>, 10 mM Tris (pH 8.3), 50 mM KCl, 8% dimethyl sulfoxide, and 0.25 units AmpliTaq DNA polymerase. The reaction was cycled for 0.5 min at 94°C, 1 min ramp to 55°C, 0.5 min at 55°C, 0.5 min ramp to 72°C, 0.5 min at 72°C, 1 min ramp to 94°C for 35 cycles.

[0138] Construction of pEXIL-4 for expression of CHEF-1 in *E. coli*: The PCR products were analyzed on a 1% agarose gel. A major band was observed at the expected size of about 390 bp. The reaction mixture was phenol/chloroform extracted then ethanol precipitated. This fragment, and plasmid pGEX-KG (Guan and Dixon, Anal. Biochem. 192: 262-67, 1991), were both digested with Eco RI and Hind III then ligated. Competent *E. coli* JM109 cells were transformed with the ligation mixture. Positive clones were confirmed by restriction digest analysis with Eco RI/Hind III. The resulting plasmid containing GST-CHEF-1 is described as pEXIL-4.

[0139] Expression of GST-CHEF-1: A single colony of *E. coli* JM109 (pEXIL-4) was grown overnight at 37°C in 2 mls Luria Broth (LB) containing 100  $\mu$ g/ml ampicillin. The overnight culture was diluted (1:50) in 10 mls of fresh LB containing ampicillin and was grown at 37°C for two hours. One ml of culture was removed as the pre-induction sample

and IPTG was added to a final concentration of 1 mM. After 3.5 hrs, one ml of culture was centrifuged. The pre- and post induced cells were resuspended in SDS/reducing buffer and both were analyzed on a 12% SDS polyacrylamide gel. Plasmid pGEX-KG was used as a positive control for expression. The gel was stained with Coomassie blue and a new protein band at about 40 kDa was observed in the post-induced but not pre-induced sample. The size of this new protein band corresponds to the expected size of the GST-CHEF-1 fusion protein.

[0140] Figure 13 shows an SDS-PAGE analysis of lysates prepared as above. Samples prior to induction with IPTG (PRE) and following a 3.5 hour (POST) induction with IPTG (POST) were analyzed with protein molecule weight markers indicated (in kDa). The induced GST-CHEF-1 fusion protein is indicated by the arrow.

## 10 EXAMPLE 10

### Expression of CHEF-1 in COS Cells and Detection using a Porcine Bone Marrow Assay

[0141] Construction of CHEF1EXP.pcd, a eukaryotic expression vector: pCHEF-1.pcd was digested to completion with Bam HI (nucleotide 2 of Figure 12) and Hpa I (nucleotide 593 of Figure 12) and the resulting 592 bp fragment recloned into the Bam HI/Eco RV site of pcDNA I/Amp. The resulting construct, pCHEF-1EXP.pcd, contained all coding sequences for CHEF-1, but was deleted of ATTTA instability sequences contained in the 3' untranslated region. Proper construction was verified by DNA sequencing.

[0142] Expression of CHEF-1 from transiently transfected COS cells: CHEF-1 was expressed by transient transfection of COS cells with pCHEF-1EXP.pcd, as described for CHEF-3 in Example 4.

[0143] Detection of CHEF-1 proliferative activity in COS cell supernatants: The detection of biological activity from COS cell supernatants transfected with pCHEF-1EXP.pcd or pcDNA I/Amp was assayed as follows. Pig bone marrow cells were plated at a concentration of 10,000 cells per well of a 96 well "U" bottomed culture plate in Iscove's Modified Dulbecco's Media containing 10% heat inactivated fetal bovine serum. The COS cell supernatants were added to this media at the appropriate percent (v/v). For three day assays, cultures were incubated for 2 days; 1 microcurie of <sup>3</sup>H-Tdr was added; and plates were harvested on day 3. For seven day assays, cultures were incubated for 6 days; 1 microcurie of <sup>3</sup>H-Tdr was added and plates were harvested on day 7. Results are counts per minute (cpm) and expressed as a mean value of triplicate wells.

[0144] Figure 14 shows the proliferative response to COS cell supernatants containing CHEF-1 in a 3 day bioassay. An approximate 10-fold increase in cellular activity was detected with a dose of 0.078% conditioned medium, but with increasing doses of CHEF-1 further increases were not observed.

[0145] Figure 15 shows the proliferative response to COS cell supernatants containing CHEF-1 in a 7 day bioassay. The results from the 7 day proliferation show a similar ~10-fold increase with only 0.078% conditioned media but additional cellular activity was detected with increasing doses of CHEF-1, to ~40-fold with >1.25% CHEF-1 containing COS cell supernatant.

## EXAMPLE 11

### Synergistic Combination of CHEF-3 with Porcine LIF

[0146] The stimulation of proliferation and colony formation by CHEF-3 in combination with porcine leukemia inhibitory factor (LIF) as compared to porcine LIF alone was examined. The capacity of LIF to stimulate the proliferation of porcine bone marrow cells [BMC] in a 7 day proliferation assay was tested over a dose range of 0-100 ng/ml with the results shown in Figure 16. A 2-3 fold increase in proliferation was detected with an optimal level of stimulation detected at 50 ng/ml. When BMC were co-cultured with a constant level of CHEF-3 [20% COS cell supernatant] against increasing doses of LIF, a LIF dose of 100 ng/ml stimulated >4-fold increase in cellular proliferation. These results demonstrate that LIF alone has a mild proliferative signal in culture containing serum but, when combined with CHEF-3, the response was enhanced to levels greater than the additive effect of each factor alone.

[0147] To further support this observation and to document that the combination of LIF and CHEF-3 stimulates not only proliferation but also the formation of colonies in a colony forming assay; BMC were cultured in the presence of CHEF-3 [10 and 20% COS cell supernatants] and increasing doses of LIF. The potential of these two factors to form colonies when combined is illustrated in Figure 17. These results show that LIF alone has only minor stimulatory activity but when combined with CHEF-3, the number of colonies increased from 11 CFU to 57 CFU when 10% CHEF-3 was used and the LIF dose was increased to 100 ng/ml. A maximal number of colonies were formed in the presence of 20% CHEF-3 and 50 ng/ml LIF. These results support the observations from the proliferation assays that the combination of LIF and CHEF-3 potentiates BMC proliferation and correlates to colony formation.

[0148] The short term effect of LIF and CHEF-3 in combination with LIF on engraftment of porcine bone marrow cells (BMC) on primate bone marrow stromal cells was also investigated. The results of the proliferation and colony formation

studies were further developed in long term bone marrow cultures (LTBMC) using primary cultures of preformed stromal cells from either porcine [allo] or primate [xeno] bone marrow. The effect of LIF on cellularity after one week in culture is illustrated in Figure 18. There was a >50% increase in cellularity of pig BMC grown on xeno stromal cells in the presence of LIF when compared to cells grown in media alone; a similar but less striking increase (24%) was detected in allo-LTBMC. Cultures grown in the absence of preformed stromal cells showed a decline in cellularity in the presence of LIF. After 7 days only a small increase in the number of progenitor cells was detected in xeno-LTBMC in the presence of LIF (Figure 19). In contrast, allo-LTBMC stimulated with LIF had a small decrease in the number progenitor cells. Cultures without preformed stromal cells showed no positive effect with LIF on progenitor cell development.

[0149] The initial studies identified that CHEF-3 in combination with LIF enhanced cell proliferation and colony formation. After one week on allo-stromal cells (Figure 20B), a significant increase in cellularity was detected in cultures grown in the presence of CHEF-3 in combination with LIF when compared to CHEF-3 alone, 740,000 cells versus 260,000 cells, respectively. However, there was not a major difference in the cellularity between CHEF-3 and CHEF-3 plus LIF stimulated cultures when BMC were grown on xeno-stromal cells (Figure 20A). In contrast, there was a greater number of progenitor cells detected in both the allo- (Figure 21B) and xeno-LTBMC (Figure 21A) cultured with CHEF-3 plus LIF than detected in cultures with CHEF-3 alone. Further, the number of progenitor cells detected in the xeno-LTBMC in the presence of CHEF-3 plus LIF was similar to the number detected in the allo-LTBMC, even though the cellularity from the xeno-LTBMC was only about 33% of that found in the allo-LTBMC (Figure 19). These results document that a combination of CHEF-3 and LIF in either allo- or xeno-LTBMC stimulates the development of progenitor cells and extends the observation for enhanced growth on xeno bone marrow stromal cells.

#### The Effect of LIF and CHEF-3 plus LIF On Long Term Maintenance of Primitive Bone Marrow Cells on Xeno-Stromal Cells.

[0150] The long term effects of LIF on cellularity and generation and maintenance of progenitor cells in xeno-LTBMC are illustrated in Figures 22A-22D. LIF for 7 weeks in xeno-LTBMC led to a higher maintenance level of cells than observed in media controls (Figure 22A). There was a subtle difference in the progenitor cell content between media and LIF treated cultures (Figure 22B) where LIF treated cultures had a greater number of progenitors at weeks 5 and 7. This indicated that LIF promoted the continued long term maintenance of progenitor cells. A two week course of LIF was compared to the 7 week course and a significant effect on cellularity was not observed (Figure 22C). Instead, there was a distinct change in the kinetics and progenitor cell content in the cultures after removing LIF from the culture media (Figure 22D). The progenitor cell number increased through week 3 and was maintained at this level through week 5 compared to the continuous treatment with LIF (Figure 22B). These results indicate that LIF has regulatory properties which limits the development or responsiveness of primitive cells into progenitor cells.

[0151] Xeno-LTBMC grown in the presence of a combination of CHEF-3 and LIF had a greater cellular and progenitor cell production over a 7 week culture period than what was observed for LTBMC treated with CHEF-3 alone (Figure 23). A striking feature of these results was the higher number of cells and progenitor cells at weeks 2 and 3 in the cultures stimulated with CHEF-3 plus LIF. There was a decrease in cellularity and progenitor cell content on week 4 which was followed by a steady increase in cellularity and a dramatic rebound in the progenitor cell level at week 7. These results identify two valuable facets of this LIF plus CHEF-3 combination, the first is the ability to enhance cellular and progenitor cell production; and the second is to favor long term engraftment in a xeno-stromal environment. This later interpretation is supported by the strong recovery of cellularity and progenitor cell content after 7 weeks in culture. Cells found at week 7 in CHEF-3 plus LIF cultures were blasts and immature cells of the granulocytic lineage, suggesting active proliferation while the cells obtained from other culture conditions were predominantly macrophages, characteristic of terminal cultures.

[0152] Figure 16. Effect of LIF and LIF plus CHEF-3 on the proliferation of pig BMC. Pig BMC were plated at a concentration of 10,000 cells/well in 96 well round bottomed tissue culture plates in Iscove's media containing 10% fetal bovine serum [FBS] (total volume/well 200ul). To one series of wells LIF was added over a series of dilutions of 0-100 ng/ml (n). To a second series of wells, media was made 20% with a COS cell supernatant containing CHEF-3 and the dilution of LIF was added (o). Cultures were grown at 37°C, 5% CO<sub>2</sub>, for 7 days. On the 6th day of culture, 1 mCi of <sup>3</sup>H-Tdr was added; cells from the plates were harvested on day 7 using a Tomtec Harvester and radioactivity was counted using a Beta-plate reader. Each data point is the mean of three wells.

[0153] Figure 17. Effect of LIF and CHEF-3 on colony formation. Pig BMC (25,000 cells/ml) were set up in cultures containing CHEF-3 (doses 0 (n), 10 (o), and 20% (u) COS cell supernatants) with dose titrations of LIF (0,25,50 and 100 ng/ml) in Iscove's media containing 30% FBS and made 1.1% in methylcellulose. 1 ml volumes were plated in duplicate and cultured for 14 days at 37°C, 5% CO<sub>2</sub>. Colonies were enumerated as having greater than 50 cells.

[0154] Figures 18 and 19. Effect of LIF and either primary allo- or xeno-stromal cells on cellularity (Figure 18) and progenitor cell development (Figure 19) after 1 week in culture. Primary stromal cells were established after 3 weeks in culture from either primate [xeno-sc] or porcine [allo-sc] BMC seeded in 24 well plates at 2 x 10<sup>6</sup> cells/ml in media

199 containing 10% FBS, 10% horse serum and 10<sup>-6</sup>M hydrocortisone [standard LTBMC media]. Media was changed weekly and the nonadherent cell population was demi-depleted. After development of a stromal layer, the primary cells were irradiated with 10 Gy, media was changed then each well was seeded with 500,000 pig BMC. Control cultures [no sc] did not contain any preformed stromal elements. The variable was either media or media containing LIF, 50 ng/ml. At the end of 7 days, the adherent and nonadherent cells were harvested from 3 wells and the number of cells per well was determined. An aliquot of cells from each well was plated in methylcellulose cultures containing 10% PHA-LCM, 2 U/ml erythropoietin, 30% FBS in Iscove's media to determine colony forming units. Colonies were counted after 14 days in culture with criteria as previously described. The plotted results are the mean of three separate experiments.

5 [0155] Figures 20 and 21. Effect of LIF, CHEF-3, or LIF+CHEF-3 and either primary allo- or xeno-stromal cells on cellularity (Figure 20A and 20B) and progenitor cell development (Figures 21A and 21B) after 1 week in culture. Cultures were established as described in detail in the legend for Figure 18. The variable is the addition of either LIF [50 ng/ml], CHEF-3 [20% COS cell supernatant] or the combination of both to standard LTBMC media. At the end of 7 days, all cells from 2 wells were harvested, cell number was determined and an aliquot of cells was plated in a colony forming assay.

10 [0156] Figures 22A-22D. A comparative long term effect of continuous versus two weeks of exogenous LIF to cellular and progenitor cell development in xeno-LTBMC. Primary primate stromal cells were prepared as previously described and seeded with 500,000 pig BMC. Cells were plated in either standard LTBMC or media containing LIF, 50 ng/ml. LTBMC were maintained by weekly feeding of the cultures using the appropriate media. All cells from 2 wells were harvested at weekly intervals to document the development of the cultures. In panels A and B, the effect of continuous LIF (o) on cellularity and progenitor cell development was compared to media (n) alone. In panels C and D, LIF (o) was maintained in the cultures for only the first two weeks. After the second week, the media was replaced with standard LTBMC media. This was compared to media alone (n) for the entire culture period.

15 [0157] Figure 23. A comparison of the long term effect of continuous CHEF-3 or CHEF-3 + LIF on the cellular and progenitor cell development in xeno-LTBMC. LTBMC were established and set up as previously described. In these experiments, standard LTBMC media was supplemented with CHEF3 [20% COS cell supernatant] or CHEF-3 [20%] and LIF [50 ng/ml]. Documentation of the development of the LTBMC was as previously described.

## SEQUENCE LISTING

30

[0158]

## (1) GENERAL INFORMATION:

35 (i) APPLICANT(S): BIOTRANSPLANT, INC.

Hawley, Robert J.

Ponath, Paul D.

Rosa, Margaret D.

Monroy, Rodney L.

40 Schacter, Bernice Z.

(ii) TITLE OF INVENTION: Enhancement of Xenograft Tolerance and Porcine Cytokines Therefor

(iii) NUMBER OF SEQUENCES: 24

(iv) CORRESPONDENCE ADDRESS:

45 (A) ADDRESSEE: Louis, Pöhlau, Lohrentz &amp; Segeth

(B) STREET: Kesslerplatz 1

(C) CITY: Nürnberg

(D) STATE:

(E) COUNTRY: Germany

50 (F) ZIP: 90489

## (v) COMPUTER READABLE FORM:

55 (A) MEDIUM TYPE: 3.5 inch diskette

(B) IBM PC Compatible

(C) OPERATING SYSTEM: MS-DOS

(D) SOFTWARE: Word 4

(vi) CURRENT APPLICATION DATA

(A) APPLICATION NUMBER: 93 925 071.8-2107  
(B) FILING DATE: October 26, 1993

5

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Segeth Wolfgang  
(B) REGISTRATION NUMBER:  
10 (C) REFERENCE/DOCKET NUMBER: 32.321ep/40/hs

10

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 0911/53 40 51  
15 (B) TELEFAX: 0911/53 86 20

15

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 21 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

25

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

30

GCGCTGCCTT TCCTTATGAA G

21

35

(3) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

40

(A) LENGTH: 24 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

TTAGGCTTTC CTATTAATGTC TACT

24

50

(4) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

55

(A) LENGTH: 633 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3

|    |  |     |
|----|--|-----|
| 5  | GCGCT GCCTTCCTT  | 15  |
|    | ATG AAG AAG ACA CAA ACT TGG ATT ATC ACT TGC ATT TAT CTT CAA CTG          | 63  |
| 10 | Met Lys Lys Thr Gln Thr Trp Ile Ile Thr Cys Ile Tyr Leu Gln Leu          |     |
|    | -25                    -20                    -15                    -10 |     |
|    | CTC CTA TTT AAT CCT CTC GTC AGA ACT CAA GGG ATC TGC AGG AAC CGT          | 111 |
| 15 | Leu Leu Phe Asn Pro Leu Val Arg Thr Gln Gly Ile Cys Arg Asn Arg          |     |
|    | -5                    1                    5                             |     |
|    | GTG ACT GAT GAT GTG AAA GAC GTT ACA AAA TTG GTG GCA AAT CTT CCA          | 159 |
| 20 | Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro          |     |
|    | 10                    15                    20                           |     |
|    | AAA GAC TAT AAG ATA ACC CTC AAA TAT GTC CCC GGG ATG GAC GTT TTG          | 207 |
| 25 | Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu          |     |
|    | 25                    30                    35                           |     |
|    |  |     |
| 30 |  |     |
|    |  |     |
| 35 |  |     |
|    |  |     |
| 40 |  |     |
|    |  |     |
| 45 |  |     |
|    |  |     |
| 50 |  |     |
|    |  |     |
| 55 |  |     |

|   |     |
|---|-----|
| CCT AGT CAT TGT TGG ATA AGC GAA ATG GTG GAA CAA CTG TCA GTC AGC | 255 |
| Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser |     |
| 5 40 45 50 55   |     |
| TTG ACT GAT CTT CTG GAC AAG TTT TCC AAT ATT TCT GAA GGC TTG AGT | 303 |
| Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser |     |
| 10 60 65 70   |     |
| AAT TAT TCT ATC ATA GAC AAA CTT GTG AAA ATT GTT GAT GAC CTC GTG | 351 |
| Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val |     |
| 15 75 80 85   |     |
| GAA TGC ATG GAA GAA CAC TCA TTT GAG AAT GTA AGA AAA TCA TCT AAG | 399 |
| Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys |     |
| 20 90 95 100  |     |
| AGC CCA GAA CCC AGG CTG TTT ACT CCT GAA AAA TTC TTT GGG ATT TTT | 447 |
| Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe |     |
| 25 105 110 115  |     |
| AAT AGA TCC ATC GAT GCC TTC AAG GAT TTG GAG ATG GTG GCA CCT AAA | 495 |
| Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys |     |
| 30 120 125 130 135  |     |
| ACT AGT GAA TGT GTG ATT TCT TCA ACA TTA ACT CCT GAA AAA GAT TCC | 543 |
| Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser |     |
| 35 140 145 150  |     |
| AGA GTC AGT GTC ACA AAA CCA TTT ATG TTA CCC CCT GTT GCA GCC AGC | 591 |
| Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser |     |
| 40 155 160 165  |     |
| TCC CTT AGG AAT GAC AGC AGT AGC AGT AAT AGG AAA GCC TAA         | 633 |
| Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala                 |     |
| 45 170 175 180  |     |

## (5) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

50 (A) LENGTH: 205 AMINO ACIDS  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: SINGLE  
 (D) TOPOLOGY: LINEAR

55 (iii) HYPOTHETICAL: YES  
 (iv) ANTI-SENSE: NO  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4

Met Lys Lys Thr Gln Thr Trp Ile Ile Thr Cys Ile Tyr Leu Gln Leu  
 -25 -20 -15 -10  
 5 Leu Leu Phe Asn Pro Leu Val Arg Thr Gln Gly Ile Cys Arg Asn Arg  
 -5 1 5  
 Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro  
 10 15 20  
 Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu  
 15 25 30 35  
 Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser  
 40 45 50 55  
 20 Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser  
 60 65 70  
 Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val  
 25 75 80 85  
 Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys  
 90 95 100  
 30 Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe  
 105 110 115  
 Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys  
 35 120 125 130 135  
 Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser  
 140 145 150  
 40 Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser  
 155 160 165  
 45 Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala  
 170 175 180  
 50 (6) INFORMATION FOR SEQ ID NO: 5:  
 (i) SEQUENCE CHARACTERISTICS:  
 55 (A) LENGTH: 10 BASES  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: SINGLE  
 (D) TOPOLOGY: LINEAR

(iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: NO  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

5

CGGAATTCCG

10

**(7) INFORMATION FOR SEQ ID NO: 6:**

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

(iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: NO  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GATCACAAAGG GATCTGCA

18

25

**(8) INFORMATION FOR SEQ ID NO: 7:**

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 10 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

35

(iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: YES  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7

40

GATCCCTTGT

10

**(9) INFORMATION FOR SEQ ID NO: 8:**

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

50

(iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: NO  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

55

TTGGGCAC TG TGGCCTGCAG C

21

(10) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 21 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

10 (iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: YES  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

15 ACAGGAAGTT TCCGGGGTTG G

21

(11) INFORMATION FOR SEQ ID NO: 10:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 798 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
25 (D) TOPOLOGY: LINEAR

(iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: NO  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

30

35

40

45

50

55

## EP 0 669 829 B1

|           |            |            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----------|------------|------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| GGCCGCTAA | AGGCTAAAGT | CCTCAGAAGG | ATG | TGG | CTG | CAG | AAC | CTG | CIT | CTC | CTG | 56  |     |     |     |     |
|           |            |            | Met | Trp | Leu | Gln | Asn | Leu | Leu | Leu | Leu |     |     |     |     |     |
| 5         |            |            |     |     | -15 |     |     |     |     | -10 |     |     |     |     |     |     |
| GGC       | ACT        | GTG        | GTC | TGC | AGC | ATC | TCC | GCT | CCC | ACC | CGC | CCA | CCC | AGC | CCT | 104 |
| Gly       | Thr        | Val        | Val | Cys | Ser | Ile | Ser | Ala | Pro | Thr | Arg | Pro | Pro | Ser | Pro |     |
| 10        |            |            |     |     | -5  |     | 1   |     |     | 5   |     |     |     |     |     |     |
| GTC       | ACC        | CGG        | CCC | TGG | CAG | CAT | GTG | GAT | GCC | ATC | AAA | GAA | GCC | CTG | AGC | 152 |
| Val       | Thr        | Arg        | Pro | Trp | Gln | His | Val | Asp | Ala | Ile | Lys | Glu | Ala | Leu | Ser |     |
| 15        |            |            |     |     | 10  |     | 15  |     |     | 20  |     |     |     |     |     |     |
| CTT       | CTA        | AAC        | AAC | AGT | AAT | GAC | ACA | GCG | GCT | GTG | ATG | AAT | GAA | ACC | GTA | 200 |
| Leu       | Leu        | Asn        | Asn | Ser | Asn | Asp | Thr | Ala | Ala | Val | Met | Asn | Glu | Thr | Val |     |
| 20        |            |            |     |     | 25  |     | 30  |     |     | 35  |     |     | 40  |     |     |     |
| GAC       | GTC        | GTC        | TGT | GAA | ATG | TTT | GAC | CCC | CAG | GAG | CCG | ACA | TGC | GTG | CAG | 248 |
| Asp       | Val        | Val        | Cys | Glu | Met | Phe | Asp | Pro | Gln | Glu | Pro | Thr | Cys | Val | Gln |     |
| 25        |            |            |     |     | 45  |     | 50  |     |     | 55  |     |     |     |     |     |     |
| ACT       | CGC        | CTG        | AAC | CTG | TAC | AAG | CAG | GGC | CTG | CGG | GGC | AGC | CTC | ACT | AGG | 296 |
| Thr       | Arg        | Leu        | Asn | Leu | Tyr | Lys | Gln | Gly | Leu | Arg | Gly | Ser | Leu | Thr | Arg |     |
| 30        |            |            |     |     | 60  |     | 65  |     |     | 70  |     |     |     |     |     |     |
| CTC       | AAG        | AGC        | CCC | TTG | ACT | CTG | TTG | GCC | AAG | CAC | TAT | GAG | CAG | CAC | TGC | 344 |
| Leu       | Lys        | Ser        | Pro | Leu | Thr | Leu | Leu | Ala | Lys | His | Tyr | Glu | Gln | His | Cys |     |
| 35        |            |            |     |     | 75  |     | 80  |     |     | 85  |     |     |     |     |     |     |
| CCC       | CTC        | ACC        | GAG | GAA | ACT | TCC | TGT | GAA | ACC | CAG | TCT | ATC | ACC | TTC | AAA | 392 |
| Pro       | Leu        | Thr        | Glu | Glu | Thr | Ser | Cys | Glu | Thr | Gln | Ser | Ile | Thr | Phe | Lys |     |
| 40        |            |            |     |     | 90  |     | 95  |     |     | 100 |     |     |     |     |     |     |

45

50

55

|     |   |     |     |  |
|-----|---|-----|-----|--|
| 5   | AGT TTC AAA GAC AGT CTG AAC AAA TTT CTT TTT ACC ATC CCC TTT GAC   | 440 |     |  |
|     | Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp   |     |     |  |
| 105 | 110   | 115 | 120 |  |
|     | TGC TGG GGG CCA GTC AAA AAG TAA AGCAGCCTGC AGCAGCCAGA AGCCAGCCTT  | 494 |     |  |
|     | Cys Trp Gly Pro Val Lys Lys                                       |     |     |  |
| 10  | 125   |     |     |  |
|     | GCCGCACGGA TTGCTCCAC TGACAGAGCC AAACCAAAC CAGGATCTC ACCGTGGAGG    | 554 |     |  |
| 15  | GACCACTGGC TGGCCAAGGC TGTAAATGGGG CACAGACTTG CCCTGGGCCA TGTTGACCT | 614 |     |  |
|     | GATACAGGCC TGGCAGGGGA AATGGCAGAT GTTTTATACC GGCAGGGATT AGCAATATTT | 674 |     |  |
|     | ATTAACCTAT TTATGTATTT TAATATTTAT TTATTTATTT ATCTATTTAT TTATTTAAGC | 734 |     |  |
| 20  | TTGAACTTCA TATTTATTCA AGATGTTTA CCATAATAAT AAATTATTTA AAATAGCGGC  | 794 |     |  |
|     | CGCT  | 798 |     |  |

## (12) INFORMATION FOR SEQ ID NO: 11:

25 (i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 144 AMINO ACIDS  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: SINGLE  
 (D) TOPOLOGY: LINEAR

35 (iii) HYPOTHETICAL: YES  
 (iv) ANTI-SENSE: NO  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

|    |   |     |     |    |
|----|---|-----|-----|----|
| 40 | Met Trp Leu Gln Asn Leu Leu Leu Leu                             |     |     |    |
|    |   | -15 | -10 |    |
|    | Gly Thr Val Val Cys Ser Ile Ser Ala Pro Thr Arg Pro Pro Ser Pro |     |     |    |
|    |   | -5  | 1   | 5  |
| 45 | Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser |     |     |    |
|    |   | 10  | 15  | 20 |
|    | Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val |     |     |    |
| 50 | 25  | 30  | 35  | 40 |

Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln  
 45 50 55  
 5 Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg  
 60 65 70  
 10 Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys  
 75 80 85  
 15 Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys  
 90 95 100  
 20 Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp  
 105 110 115 120  
 25 Cys Trp Gly Pro Val Lys Lys  
 125

## (13) INFORMATION FOR SEQ ID NO: 12:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 BASES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- 30 (D) TOPOLOGY: LINEAR

(iii) HYPOTHETICAL: NO  
 (iv) ANTI-SENSE: NO  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

29

CGACGGTACC GGCTCCACC CGCCCACCC

## (14) INFORMATION FOR SEQ ID NO: 13:

40 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 BASES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- 45 (D) TOPOLOGY: LINEAR

(iii) HYPOTHETICAL: NO  
 (iv) ANTI-SENSE: YES  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

40

AGGATCTAGA GGATCCTCAT CACTTTTGA CTGGCCCCA

55

## (15) INFORMATION FOR SEQ ID NO: 14:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

10 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

15 TGGTTCCAG CAGTCAAAGG G

21

16 (16) INFORMATION FOR SEQ ID NO: 15:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

25 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

30 ACATCTGCCA TTTCCCCTGC C

21

35 (17) INFORMATION FOR SEQ ID NO: 16:

40 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

45 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16

46 CTATGGAGGT TCCATGTCAG ATAAAG

26

50 (18) INFORMATION FOR SEQ ID NO: 17:

55 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 BASES  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17

5

ATGTTCA~~T~~TT GTACCTC

17

(19) INFORMATION FOR SEQ ID NO: 18:

10

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 BASES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

15

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18

20

AGACAGGATC CATCGTACCG

20

(20) INFORMATION FOR SEQ ID NO: 19:

25

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 BASES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19

30

CTCATT~~C~~AGA AGGAGCAGGC

20

40

(21) INFORMATION FOR SEQ ID NO: 20:

45

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 760
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20

50

55

|  |     |
|--|-----|
| GGA TCCATCGTAC CGGCCAAAC ATG AGC AGC CTC CCC CTT ATG CAT CTG CTC | 53  |
| Met Ser Ser Leu Pro Leu Met His Leu Leu                          |     |
| 5 -20 -15  |     |
| CTG CTG CTG CTC ACA CTC CAT GCT CCT CAG GCA CAG GGG ATG CCT ACC  | 101 |
| Leu Leu Leu Leu Thr Leu His Ala Pro Gln Ala Gln Gly Met Pro Thr  |     |
| 10 -10 -5 1  |     |
| ACA ACA CTC CAA CCT AAA AAC TAC CTT GCC ATG ATC CAG GAA ATT ACA  | 149 |
| Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr  |     |
| 15 5 10 15   |     |
| AGA AGC CTA GAG AAC CTA ACT GTG ACT TCA AAT AAA TCC TTG ACG TTG  | 197 |
| Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu  |     |
| 20 25 30 35  |     |
| 25   |     |
| 30   |     |
| 35   |     |
| 40   |     |
| 45   |     |
| 50   |     |
| 55   |     |

|  |     |
|--|-----|
| AAT GAG CTC GAA ACC CTG GTG AAT AAC ACT CTT CTG AGA CCA AAC CTG    | 245 |
| Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu    |     |
| 5 40 45 50   |     |
| GAA GCA TTC GTG ACA TTT GCT GAA AAC CAC TTA AAA AAT ATT TCA GGA    | 293 |
| Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly    |     |
| 10 55 60 65  |     |
| ATC AAG AAA AAC CTT GAG AAA TTC CGG CCA ATC CTG CCC ACG TCT ATG    | 341 |
| Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met    |     |
| 15 70 75 80  |     |
| TCC ACG GAA GAG CCA ATC TCT ATT GAG GAG GGC GAC CTT GGT GAT TTC    | 389 |
| Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe    |     |
| 20 85 90 95  |     |
| CGG GCG AAA CTG ATG GAG TAT CTG GTT GTC CTT AGA GAC TCT CTG AAA    | 437 |
| Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys    |     |
| 25 100 105 110 115   |     |
| CCC ATG ATC ACA GAG CCC TAA AATCTGAAGT GTGAACTCCA GCTCTCTCTC       | 488 |
| Pro Met Ile Thr Glu Pro  |     |
| 30 120   |     |
| TGGAGCCCTG GAACGTCAGG AACAGCAGAT CGTCCTAAGA TGCCTGGACC GTCTCTCACA  | 548 |
| CCATCCAGGA CTGACGTTTT CTCCCTGTGGA GTCTGTTGAA TTGTTAACTA TCTAATCCCT | 608 |
| 35 GAAATGTGCA GCCCCATTG TCCTTTGCG ATTAGTTCT CATTCTTATT GTATTGAGGC  | 668 |
| TATTTATTAA TGTATGTATT TATTTATTAT CTTGTGCAAT GTGAAATGTA TTTACTTAAC  | 728 |
| AGAGAAGCCA TGGCTGCTC CTTCTGAATG AG                                 | 760 |
| 40   |     |

## (22) INFORMATION FOR SEQ ID NO: 21:

## (i) SEQUENCE CHARACTERISTICS:

45 (A) LENGTH: 144 AMINO ACIDS  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: SINGLE  
 (D) TOPOLOGY: LINEAR

50 (iii) HYPOTHETICAL: YES  
 (iv) ANTI-SENSE: NO  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Met | Ser | Ser | Leu | Pro | Leu | Met | His | Leu | Leu |     |     |     |     |     |     |
|    |     |     |     |     |     | -20 |     |     |     | -15 |     |     |     |     |     |     |
| 5  | Leu | Leu | Leu | Leu | Thr | Leu | His | Ala | Pro | Gln | Ala | Gln | Gly | Met | Pro | Thr |
|    |     |     |     |     | -10 |     |     | -5  |     |     |     |     |     | 1   |     |     |
| 10 | Thr | Thr | Leu | Gln | Pro | Lys | Asn | Tyr | Leu | Ala | Met | Ile | Gln | Glu | Ile | Thr |
|    |     |     |     |     | 5   |     |     | 10  |     |     | 15  |     |     |     |     |     |
| 15 | Arg | Ser | Leu | Glu | Asn | Leu | Thr | Val | Thr | Ser | Asn | Lys | Ser | Leu | Thr | Leu |
|    |     |     |     |     | 20  |     |     | 25  |     |     | 30  |     |     |     | 35  |     |
| 20 | Asn | Glu | Leu | Glu | Thr | Leu | Val | Asn | Asn | Thr | Leu | Leu | Arg | Pro | Asn | Leu |
|    |     |     |     |     | 40  |     |     | 45  |     |     | 50  |     |     |     |     |     |
| 25 | Glu | Ala | Phe | Val | Thr | Phe | Ala | Glu | Asn | His | Leu | Lys | Asn | Ile | Ser | Gly |
|    |     |     |     |     | 55  |     |     | 60  |     |     | 65  |     |     |     |     |     |
| 30 | Ile | Lys | Lys | Asn | Leu | Glu | Lys | Phe | Arg | Pro | Ile | Leu | Pro | Thr | Ser | Met |
|    |     |     |     |     | 70  |     |     | 75  |     |     | 80  |     |     |     |     |     |
| 35 | Ser | Thr | Glu | Glu | Pro | Ile | Ser | Ile | Glu | Glu | Gly | Asp | Leu | Gly | Asp | Phe |
|    |     |     |     |     | 85  |     |     | 90  |     |     | 95  |     |     |     |     |     |
| 40 | Arg | Ala | Lys | Leu | Met | Glu | Tyr | Leu | Val | Val | Leu | Arg | Asp | Ser | Leu | Lys |
|    |     |     |     |     | 100 |     |     | 105 |     |     | 110 |     |     |     | 115 |     |
| 45 | Pro | Met | Ile | Thr | Glu | Pro |     |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     | 120 |     |     |     |     |     |     |     |     |     |     |     |

## (23) INFORMATION FOR SEQ ID NO: 22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 BASES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22

50 GGGGAATTCA TATGCCTACC ACAACACTC

29

## (24) INFORMATION FOR SEQ ID NO: 23

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 BASES
- (B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

5 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

10 **CCCAAGCTTG GATCCTATTA GGGCTCTGTG ATCATGGG**

28

**(25) INFORMATION FOR SEQ ID NO: 24**

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 BASES

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: SINGLE

(D) TOPOLOGY: LINEAR

20 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

25 **AGGATGTGGC TGCAGAACCT G**

21

**Claims**

30 1. A polynucleotide comprising (a) a polynucleotide sequence which codes for a polypeptide comprising the following amino acids:

35

40

45

50

55

Gln Gly Ile Cys Arg Asn Arg  
 1 5

5 Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro  
 10 15 20

Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu  
 10 25 30 35

15 Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser  
 40 45 50 55

Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser  
 15 60 65 70

Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val  
 20 75 80 85

Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys  
 25 90 95 100

Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe  
 105 110 115

Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys  
 120 125 130 135

30 Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser  
 140 145 150

Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser  
 35 155 160 165

40 Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala  
 170 175 180

or

(b) the complement of (a)

45 2. The polynucleotide of claim 1 wherein the polynucleotide sequence codes for said polypeptide.

3. A polynucleotide comprising a polynucleotide selected from the group consisting of:

50 (a) a polynucleotide sequence which is at least 90 % identical to a polynucleotide coding for a polypeptide comprising the following amino acid sequence:

|    |   |                                 |     |
|----|---|---------------------------------|-----|
|    |   | Ala Pro Thr Arg Pro Pro Ser Pro |     |
|    |   | 1                               | 5   |
| 5  | Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser |                                 |     |
|    | 10  | 15                              | 20  |
|    | Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val |                                 |     |
| 10 | 25  | 30                              | 35  |
|    |   |                                 | 40  |
|    |   |                                 |     |
|    | Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln |                                 |     |
| 15 | 45  | 50                              | 55  |
|    | Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg |                                 |     |
|    | 60  | 65                              | 70  |
|    | Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys |                                 |     |
| 20 | 75  | 80                              | 85  |
|    | Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys |                                 |     |
|    | 90  | 95                              | 100 |
| 25 | Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp |                                 |     |
|    | 105   | 110                             | 115 |
|    | Cys Trp Gly Pro Val Lys Lys                                     |                                 |     |
| 30 | 125   |                                 |     |

or

(b) a polynucleotide complementary to (a).

35 4. A polynucleotide of claim 3 wherein the polynucleotide codes for a polypeptide comprising the following amino acids:

40

45

50

55

Ala Pro Thr Arg Pro Pro Ser Pro  
 1 5

5 Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser  
 10 15 20

10 Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val  
 25 30 35 40

15 Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln  
 45 50 55

20 Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg  
 60 65 70

25 Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys  
 75 80 85

30 Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys  
 90 95 100

35 Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp  
 105 110 115 120

40 Cys Trp Gly Pro Val Lys Lys  
 125

5. A polynucleotide of claim 3 wherein the polynucleotide sequence is at least 90 % identical to a polynucleotide comprising the following sequence:

GCT CCC ACC CGC CCA CCC AGC CCT 24  
 1 5

40 GTC ACC CGG CCC TGG CAG CAT GTG GAT GCC ATC AAA GAA GCC CTG AGC 72  
 10 15 20

45

50

55

|   |   |   |
|---|---|---|
| 5 | CTT CTA AAC AAC AGT AAT GAC ACA GCG GCT GTG ATG AAT GAA ACC GTA<br>25 30 35 40<br>GAC GTC GTC TGT GAA ATG TTT GAC CCC CAG GAG CCG ACA TGC GTG CAG<br>45 50 55<br>ACT CGC CTG AAC CTG TAC AAG CAG GGC CTG CGG GGC AGC CTC ACT AGG<br>10 60 65 70<br>CTC AAG AGC CCC TTG ACT CTG TTG GCC AAG CAC TAT GAG CAG CAC TGC<br>75 80 85<br>15 CCC CTC ACC GAG GAA ACT TCC TGT GAA ACC CAG TCT ATC ACC TTC AAA<br>90 95 100<br>AGT TTC AAA GAC AGT CTG AAC AAA TTT CTT TTT ACC ATC CCC TTT GAC<br>20 105 110 115 120<br>TGC TGG GGG CCA GTC AAA AAG<br>Cys Trp Gly Pro Val Lys Lys<br>125<br>25 | 120<br>168<br>216<br>264<br>312<br>360<br>120 |
|---|---|---|

## 6. The polynucleotide of claim 5 comprising the following sequence:

|    |  |   |
|----|--|---|
| 30 | GCT CCC ACC CGC CCA CCC AGC CCT<br>1 5<br>GTC ACC CGG CCC TGG CAG CAT GTG GAT GCC ATC AAA GAA GCC CTG AGC<br>10 15 20<br>35 CTT CTA AAC AAC AGT AAT GAC ACA GCG GCT GTG ATG AAT GAA ACC GTA<br>25 30 35 40<br>GAC GTC GTC TGT GAA ATG TTT GAC CCC CAG GAG CCG ACA TGC GTG CAG<br>40 45 50 55<br>ACT CGC CTG AAC CTG TAC AAG CAG GGC CTG CGG GGC AGC CTC ACT AGG<br>60 65 70<br>45 CTC AAG AGC CCC TTG ACT CTG TTG GCC AAG CAC TAT GAG CAG CAC TGC<br>75 80 85<br>45 Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys<br>50 90 95 100<br>50 CCC CTC ACC GAG GAA ACT TCC TGT GAA ACC CAG TCT ATC ACC TTC AAA<br>312 | 24<br>72<br>120<br>168<br>216<br>264<br>120 |
|----|--|---|

AGT TTC AAA GAC AGT CTG AAC AAA TTT CTT TTT ACC ATC CCC TTT GAC 360  
 105 110 115 120  
 5 TGC TGG GGG CCA GTC AAA AAG  
 125

7. A polynucleotide comprising (a) a polynucleotide sequence that is at least 90 % identical to a polynucleotide which  
 10 codes for a polypeptide comprising the following amino acids:

Met Pro Thr  
 15  
 1  
 Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr  
 5 10 15  
 20 Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu  
 20 25 30 35  
 Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu  
 25 40 45 50  
 Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly  
 55 60 65  
 Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met  
 30 70 75 80  
 Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe  
 85 90 95  
 35 Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys  
 100 105 110 115  
 Pro Met Ile Thr Glu Pro  
 40 120

or

(b) the complement of (a)

45 8. Polynucleotide according to claim 7 coding for a polypeptide comprising the following amino acids:

50

55

9. The polynucleotide of claim 7 comprising a polynucleotide sequence that is at least 90% identical to a polynucleotide comprising the following sequence:

|    |   |             |     |    |
|----|---|-------------|-----|----|
| 35 |   | ATG CCT ACC | 9   |    |
|    |   | 1           |     |    |
|    | ACA ACA CTC CAA CCT AAA AAC TAC CTT GCC ATG ATC CAG GAA ATT ACA |             | 57  |    |
| 40 | 5   | 10          | 15  |    |
|    | AGA AGC CTA GAG AAC CTA ACT GTG ACT TCA AAT AAA TCC TTG ACG TTG |             | 105 |    |
|    | 20  | 25          | 30  | 35 |
| 45 | AAT GAG CTC GAA ACC CTG GTG AAT AAC ACT CTT CTG AGA CCA AAC CTG |             | 153 |    |
|    | 40  | 45          | 50  |    |
|    | GAA GCA TTC GTG ACA TTT GCT GAA AAC CAC TTA AAA AAT ATT TCA GGA |             | 201 |    |
| 50 | 55  | 60          | 65  |    |

|   |     |     |     |
|---|-----|-----|-----|
| ATC AAG AAA AAC CTT GAG AAA TTC CGG CCA ATC CTG CCC ACG TCT ATG   | 249 |     |     |
| 70  | 75  | 80  |     |
| 5 TCC ACG GAA GAG CCA ATC TCT ATT GAG GAG GGC GAC CTT GGT GAT TTC | 297 |     |     |
| 85  | 90  | 95  |     |
| CGG GCG AAA CTG ATG GAG TAT CTG GTT GTC CTT AGA GAC TCT CTG AAA   | 345 |     |     |
| 10 100  | 105 | 110 | 115 |
| CCC ATG ATC ACA GAG CCC   | 396 |     |     |
| 120   |     |     |     |

15 10. The polynucleotide of claim 2 having the following sequence:

|    |   |     |     |     |
|----|---|-----|-----|-----|
| 20 | ATG AAG AAG ACA CAA ACT TGG ATT ATC ACT TGC ATT TAT CTT CAA CTG | 63  |     |     |
|    | Met Lys Lys Thr Gln Thr Trp Ile Ile Thr Cys Ile Tyr Leu Gln Leu |     |     |     |
|    | -25   | -20 | -15 | -10 |
| 25 | CTC CTA TTT AAT CCT CTC GTC AGA ACT CAA GGG ATC TGC AGG AAC CGT | 111 |     |     |
|    | Leu Leu Phe Asn Pro Leu Val Arg Thr Gln Gly Ile Cys Arg Asn Arg |     |     |     |
|    | -5  | 1   | 5   |     |
| 30 | GTG ACT GAT GAT GTG AAA GAC GTT ACA AAA TTG GTG GCA AAT CTT CCA | 159 |     |     |
|    | Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro |     |     |     |
|    | 10  | 15  | 20  |     |
| 35 | AAA GAC TAT AAG ATA ACC CTC AAA TAT GTC CCC GGG ATG GAC GTT TTG | 207 |     |     |
|    | Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu |     |     |     |
|    | 25  | 30  | 35  |     |
| 40 | CCT AGT CAT TGT TGG ATA AGC GAA ATG GTG GAA CAA CTG TCA GTC AGC | 255 |     |     |
|    | Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser |     |     |     |
|    | 40  | 45  | 50  | 55  |
| 45 | TTG ACT GAT CTT CTG GAC AAG TTT TCC AAT ATT TCT GAA GGC TTG AGT | 303 |     |     |
|    | Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser |     |     |     |
|    | 60  | 65  | 70  |     |

50

55

|  |     |
|--|-----|
| AAT TAT TCT ATC ATA GAC AAA CTT GTG AAA ATT GTT GAT GAC CTC GTG    | 351 |
| Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val    |     |
| 5 75 80 85   |     |
| GAA TGC ATG GAA GAA CAC TCA TTT GAG AAT GTA AGA AAA TCA TCT AAG    | 399 |
| Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys    |     |
| 10 90 95 100   |     |
| AGC CCA GAA CCC AGG CTG TTT ACT CCT GAA AAA TTC TTT GGG ATT TTT    | 447 |
| Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe    |     |
| 15 105 110 115   |     |
| AAT AGA TCC ATC GAT GCC TTC AAG GAT TTG GAG ATG GTG GCA CCT AAA    | 495 |
| Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys    |     |
| 20 120 125 130 135   |     |
| ACT AGT GAA TGT GTG ATT TCT TCA ACA TTA ACT CCT GAA AAA GAT TCC    | 543 |
| Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser    |     |
| 140 145 150  |     |
| 25 AGA GTC AGT GTC ACA AAA CCA TTT ATG TTA CCC CCT GTT GCA GCC AGC | 591 |
| Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser    |     |
| 155 160 165  |     |
| 30 TCC CTT AGG AAT GAC AGC AGT AGC AGT AAT AGG AAA GCC TAA         | 633 |
| Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala                    |     |
| 170 175 180  |     |

35 11. An expression vector comprising the polynucleotide of claim 1, and a regulatory sequence effective to support transcription thereof.

12. An expression vector comprising the polynucleotide of claim 3 and a regulatory sequence effective to support transcription thereof.

40 13. An expression vector comprising the polynucleotide of claim 7 and a regulatory sequence effective to support transcription thereof.

14. The expression vector of claim 11 which further comprises a coding sequence for at least one additional cytokine and a transcription regulatory sequence therefor.

45 15. The expression vector of claim 12 which further comprises a coding sequence for at least one additional cytokine and a transcription regulatory sequence therefor.

50 16. Isolated porcine bone marrow cells that contain an expression vector comprising the polynucleotide of claim 1.

17. Isolated porcine bone marrow cells that contain an expression vector comprising the polynucleotide of claim 3.

18. Isolated porcine bone marrow cells that contain an expression vector comprising the polynucleotide of claim 7.

55 19. An expression vector comprising the polynucleotide of claim 2.

20. An expression vector comprising the polynucleotide of claim 4.

21. An expression vector comprising the polynucleotide of claim 8.

22. The polynucleotide of claim 9 comprising the sequence:

5

|    |   |             |     |
|----|---|-------------|-----|
|    |   | ATG CCT ACC | 101 |
|    |   | 1           |     |
| 10 | ACA ACA CTC CAA CCT AAA AAC TAC CTT GCC ATG ATC CAG GAA ATT ACA   |             | 149 |
|    | 5   | 10          | 15  |
|    | AGA AGC CTA GAG AAC CTA ACT GTG ACT TCA AAT AAA TCC TTG ACG TTG   |             | 197 |
| 15 | 20  | 25          | 30  |
|    |   |             | 35  |
|    | AAT GAG CTC GAA ACC CTG GTG AAT AAC ACT CTT CTG AGA CCA AAC CTG   |             | 245 |
| 20 | 40  | 45          | 50  |
|    | GAA GCA TTC GTG ACA TTT GCT GAA AAC CAC TTA AAA AAT ATT TCA GGA   |             | 293 |
|    | 55  | 60          | 65  |
| 25 | ATC AAG AAA AAC CTT GAG AAA TTC CGG CCA ATC CTG CCC ACG TCT ATG   |             | 341 |
|    | 70  | 75          | 80  |
|    | TCC ACG GAA GAG CCA ATC TCT ATT GAG GAG GGC GAC CTT GGT GAT TTC   |             | 389 |
| 30 | 85  | 90          | 95  |
|    | CGG GCG AAA CTG ATG GAG TAT CTG GTT GTC CTT AGA GAC TCT CTG AAA   |             | 437 |
|    | 100   | 105         | 110 |
| 35 | 115   |             |     |
|    | CCC ATG ATC ACA GAG CCC TAA AATCTGAAGT GTGAACCTCCA GCTCTCTCTC     |             | 488 |
|    | 120   |             |     |
|    | TGGAGCCCTG GAACGTCAGG AACAGCAGAT CGTCCTAAGA TGCCTGGACC GTCTCTCACA |             | 548 |
|    | CCATCCAGGA CTGACGTTT CTCCTGTGGA GTCTGTTGAA TTGTTAACTA TCTAATCCCT  |             | 608 |
| 40 | GAAATGTGCA GCCCCATTG TCCCTTTGCG ATTAGGTTCT CATTCTTATT GTATTGAGGC  |             | 668 |
|    | TATTTATTCA TGTATGTATT TATTTATTAT CTTGTGCAAT GTGAAATGTA TTTACTTAAC |             | 728 |
|    | AGAGAAGCCA TGGCCTGCTC CTTCTGAATG AG                               |             | 760 |

45

23. A polypeptide, comprising a polypeptide sequence which is at least 90 % identical to a polypeptide comprising the following amino acid sequence:

50

55

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    |     | Gln | Gly | Ile | Cys | Arg | Asn | Arg |     |     |     |     |     |     |     |     |
|    |     | 1   |     |     | 5   |     |     |     |     |     |     |     |     |     |     |     |
| 5  | Val | Thr | Asp | Asp | Val | Lys | Asp | Val | Thr | Lys | Leu | Val | Ala | Asn | Leu | Pro |
|    |     | 10  |     |     | 15  |     |     |     | 20  |     |     |     |     |     |     |     |
| 10 | Lys | Asp | Tyr | Lys | Ile | Thr | Leu | Lys | Tyr | Val | Pro | Gly | Met | Asp | Val | Leu |
|    | 25  |     |     | 30  |     |     | 35  |     |     |     |     |     |     |     |     |     |
| 15 | Pro | Ser | His | Cys | Trp | Ile | Ser | Glu | Met | Val | Glu | Gln | Leu | Ser | Val | Ser |
|    | 40  |     |     | 45  |     |     | 50  |     |     | 55  |     |     |     |     |     |     |
| 20 | Leu | Thr | Asp | Leu | Leu | Asp | Lys | Phe | Ser | Asn | Ile | Ser | Glu | Gly | Leu | Ser |
|    |     | 60  |     |     | 65  |     |     | 70  |     |     |     |     |     |     |     |     |
| 25 | Asn | Tyr | Ser | Ile | Ile | Asp | Lys | Leu | Val | Lys | Ile | Val | Asp | Asp | Leu | Val |
|    |     | 75  |     |     | 80  |     |     | 85  |     |     |     |     |     |     |     |     |
| 30 | Glu | Cys | Met | Glu | Glu | His | Ser | Phe | Glu | Asn | Val | Arg | Lys | Ser | Ser | Lys |
|    |     | 90  |     |     | 95  |     |     | 100 |     |     |     |     |     |     |     |     |
| 35 | Ser | Pro | Glu | Pro | Arg | Leu | Phe | Thr | Pro | Glu | Phe | Phe | Gly | Ile | Phe |     |
|    |     | 105 |     |     | 110 |     |     | 115 |     |     |     |     |     |     |     |     |
| 40 | Asn | Arg | Ser | Ile | Asp | Ala | Phe | Lys | Asp | Leu | Glu | Met | Val | Ala | Pro | Lys |
|    |     | 120 |     |     | 125 |     |     | 130 |     |     | 135 |     |     |     |     |     |
| 45 | Thr | Ser | Glu | Cys | Val | Ile | Ser | Ser | Thr | Leu | Thr | Pro | Glu | Lys | Asp | Ser |
|    |     | 140 |     |     | 145 |     |     | 150 |     |     |     |     |     |     |     |     |
| 50 | Arg | Val | Ser | Val | Thr | Lys | Pro | Phe | Met | Leu | Pro | Pro | Val | Ala | Ala | Ser |
|    |     | 155 |     |     | 160 |     |     | 165 |     |     |     |     |     |     |     |     |
| 55 | Ser | Leu | Arg | Asn | Asp | Ser | Ser | Ser | Asn | Arg | Lys | Ala |     |     |     |     |
|    |     | 170 |     |     | 175 |     |     | 180 |     |     |     |     |     |     |     |     |

24. The polypeptide of claim 23 comprising the following amino acids:

45

50

55

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    |     | Gln | Gly | Ile | Cys | Arg | Asn | Arg |     |     |     |     |     |     |     |     |
|    |     | 1   |     |     | 5   |     |     |     |     |     |     |     |     |     |     |     |
| 5  | Val | Thr | Asp | Asp | Val | Lys | Asp | Val | Thr | Lys | Leu | Val | Ala | Asn | Leu | Pro |
|    |     | 10  |     |     | 15  |     |     |     | 20  |     |     |     |     |     |     |     |
|    | Lys | Asp | Tyr | Lys | Ile | Thr | Leu | Lys | Tyr | Val | Pro | Gly | Met | Asp | Val | Leu |
| 10 |     | 25  |     |     | 30  |     |     | 35  |     |     |     |     |     |     |     |     |
|    | Pro | Ser | His | Cys | Trp | Ile | Ser | Glu | Met | Val | Glu | Gln | Leu | Ser | Val | Ser |
|    |     | 40  |     |     | 45  |     |     | 50  |     |     | 55  |     |     |     |     |     |
| 15 | Leu | Thr | Asp | Leu | Leu | Asp | Lys | Phe | Ser | Asn | Ile | Ser | Glu | Gly | Leu | Ser |
|    |     | 60  |     |     | 65  |     |     | 70  |     |     |     |     |     |     |     |     |
|    | Asn | Tyr | Ser | Ile | Ile | Asp | Lys | Leu | Val | Lys | Ile | Val | Asp | Asp | Leu | Val |
| 20 |     | 75  |     |     | 80  |     |     | 85  |     |     |     |     |     |     |     |     |
|    | Glu | Cys | Met | Glu | Glu | His | Ser | Phe | Glu | Asn | Val | Arg | Lys | Ser | Ser | Lys |
|    |     | 90  |     |     | 95  |     |     | 100 |     |     |     |     |     |     |     |     |
|    | Ser | Pro | Glu | Pro | Arg | Leu | Phe | Thr | Pro | Glu | Lys | Phe | Phe | Gly | Ile | Phe |
| 25 |     | 105 |     |     | 110 |     |     | 115 |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 30 | Asn | Arg | Ser | Ile | Asp | Ala | Phe | Lys | Asp | Leu | Glu | Met | Val | Ala | Pro | Lys |
|    |     | 120 |     |     | 125 |     |     | 130 |     |     | 135 |     |     |     |     |     |
|    | Thr | Ser | Glu | Cys | Val | Ile | Ser | Ser | Thr | Leu | Thr | Pro | Glu | Lys | Asp | Ser |
|    |     | 140 |     |     | 145 |     |     | 150 |     |     |     |     |     |     |     |     |
| 35 | Arg | Val | Ser | Val | Thr | Lys | Pro | Phe | Met | Leu | Pro | Pro | Val | Ala | Ala | Ser |
|    |     | 155 |     |     | 160 |     |     | 165 |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 40 | Ser | Leu | Arg | Asn | Asp | Ser | Ser | Ser | Asn | Arg | Lys | Ala |     |     |     |     |
|    |     | 170 |     |     | 175 |     |     | 180 |     |     |     |     |     |     |     |     |

25. A polypeptide comprising a polypeptide sequence which is at least 90 % identical to a polypeptide comprising the following amino acid sequence:

|    |   |                                 |     |
|----|---|---------------------------------|-----|
|    |   | Ala Pro Thr Arg Pro Pro Ser Pro |     |
|    |   | 1                               | 5   |
| 5  | Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser |                                 |     |
|    | 10  | 15                              | 20  |
|    | Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val |                                 |     |
| 10 | 25  | 30                              | 35  |
|    |   |                                 | 40  |
|    | Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln |                                 |     |
| 15 | 45  | 50                              | 55  |
|    | Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg |                                 |     |
|    | 60  | 65                              | 70  |
|    | Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys |                                 |     |
| 20 | 75  | 80                              | 85  |
|    | Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys |                                 |     |
|    | 90  | 95                              | 100 |
| 25 | Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp |                                 |     |
|    | 105   | 110                             | 115 |
|    | Cys Trp Gly Pro Val Lys Lys                                     |                                 |     |
| 30 | 125   |                                 |     |

26. The polypeptide of claim 25 comprising the following amino acids:

35

40

45

50

55

Ala Pro Thr Arg Pro Pro Ser Pro

1 5

5 Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser

10 15 20

10 Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val

15 25 30 35 40

Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln

15 45 50 55

Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg

20 60 65 70

Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys

25 75 80 85

Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys

30 90 95 100

Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp

35 105 110 115 120

Cys Trp Gly Pro Val Lys Lys

40 125

27. A polypeptide comprising a sequence which is at least 90 % identical to a polypeptide comprising the following amino acid sequence:

35

Met Pro Thr

1

40 Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr

45 5 10 15

Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu

50 20 25 30 35

Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu  
 40 45 50  
 5 Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly  
 55 60 65  
 Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met  
 10 70 75 80  
 Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe  
 85 90 95  
 15 Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys  
 100 105 110 115  
 Pro Met Ile Thr Glu Pro  
 20 120

28. The polypeptide of claim 27 comprising the following amino acids:

25 Met Pro Thr  
 1  
 Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr  
 30 5 10 15  
 Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu  
 20 25 30 35  
 35 Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu  
 40 45 50  
 Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly  
 55 60 65  
 40 Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met  
 70 75 80  
 Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe  
 45 85 90 95  
 Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys  
 100 105 110 115  
 50 Pro Met Ile Thr Glu Pro  
 120

29. Use of one or more polypeptides according to any of claims 23 to 28 for the preparation of a composition for  
 55 promoting engraftment of porcine bone marrow cells in a xenogeneic recipient.

30. Use of one or more polynucleotides according to any of claims 1 to 10 for the preparation of a composition for  
 promoting engraftment of porcine bone marrow cells in a xenogeneic recipient.

## Patentansprüche

1. Polynukleotid, umfassend (a) eine Polynukleotidsequenz, die für ein Polypeptid kodiert, das die folgenden Aminosäuren umfasst:

5

|    |   |                             |
|----|---|-----------------------------|
|    |   | Gln Gly Ile Cys Arg Asn Arg |
|    |   | 1 5                         |
| 10 | Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro |                             |
|    | 10 15 20  |                             |
| 15 | Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu |                             |
|    | 25 30 35  |                             |
| 20 | Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser |                             |
|    | 40 45 50 55   |                             |
| 25 | Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser |                             |
|    | 60 65 70  |                             |
| 30 | Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val |                             |
|    | 75 80 85  |                             |
| 35 | Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys |                             |
|    | 90 95 100   |                             |
| 40 | Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe |                             |
|    | 105 110 115   |                             |
| 45 | Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys |                             |
|    | 120 125 130 135   |                             |
| 50 | Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser |                             |
|    | 140 145 150   |                             |
| 55 | Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser |                             |
|    | 155 160 165   |                             |
| 60 | Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala                 |                             |
|    | 170 175 180   |                             |

oder

(b) das Komplement von (a).

2. Polynukleotid gemäß Anspruch 1, wobei die Polynukleotidsequenz für das Polypeptid kodiert.

50

3. Polynukleotid, umfassend ein Polynukleotid, ausgewählt aus der Gruppe bestehend aus:

(a) einer Polynukleotidsequenz, die wenigstens zu 90 % identisch zu einem Polynukleotid ist, das für ein Polypeptid kodiert, welches die folgende Aminosäuresequenz umfasst:

55

Ala Pro Thr Arg Pro Pro Ser Pro  
 1 5

5 Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser  
 10 15 20

Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val  
 25 30 35 40

10

Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln  
 45 50 55

15 Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg  
 60 65 70

Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys  
 75 80 85

20 Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys  
 90 95 100

25 Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp  
 105 110 115 120

Cys Trp Gly Pro Val Lys Lys  
 125

30 oder

(b) einem zu (a) komplementären Polynucleotid.

4. Polynucleotid gemäß Anspruch 3, wobei das Polynucleotid für ein Polypeptid kodiert, das die folgenden Aminosäuren umfasst:

40

45

50

55

|    |   |     |                                 |
|----|---|-----|---------------------------------|
|    |   |     | Ala Pro Thr Arg Pro Pro Ser Pro |
|    |   | 1   | 5                               |
| 5  | Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser |     |                                 |
|    | 10  | 15  | 20                              |
|    | Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val |     |                                 |
| 10 | 25  | 30  | 35                              |
|    | Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln |     |                                 |
|    | 45  | 50  | 55                              |
| 15 | Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg |     |                                 |
|    | 60  | 65  | 70                              |
|    | Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys |     |                                 |
| 20 | 75  | 80  | 85                              |
|    | Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys |     |                                 |
|    | 90  | 95  | 100                             |
|    | Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp |     |                                 |
| 25 | 105   | 110 | 115                             |
|    | Cys Trp Gly Pro Val Lys Lys                                     |     |                                 |
|    | 125   |     |                                 |

30 5. Polynukleotid gemäß Anspruch 3, wobei die Polynukleotidsequenz zu wenigstens 90 % identisch zu einem Polynukleotid ist, welches die folgende Sequenz umfasst:

|    |   |    |
|----|---|----|
|    | GCT CCC ACC CGC CCA CCC AGC CCT                                 | 24 |
| 35 | 1   | 5  |
|    | GTC ACC CGG CCC TGG CAG CAT GTG GAT GCC ATC AAA GAA GCC CTG AGC | 72 |
|    | 10  | 15 |
|    | 20  |    |

40

45

50

55

|    |  |     |
|----|--|-----|
| 5  | CTT CTA AAC AAC AGT AAT GAC ACA GCG GCT GTG ATG AAT GAA ACC GTA<br>25 30 35 40     | 120 |
|    | GAC GTC GTC TGT GAA ATG TTT GAC CCC CAG GAG CCG ACA TGC GTG CAG<br>45 50 55        | 168 |
| 10 | ACT CGC CTG AAC CTG TAC AAG CAG GGC CTG CGG GGC AGC CTC ACT AGG<br>60 65 70        | 216 |
|    | CTC AAG AGC CCC TTG ACT CTG TTG GCC AAG CAC TAT GAG CAG CAC TGC<br>75 80 85        | 264 |
| 15 | CCC CTC ACC GAG GAA ACT TCC TGT GAA ACC CAG TCT ATC ACC TTC AAA<br>90 95 100       | 312 |
|    | AGT TTC AAA GAC AGT CTG AAC AAA TTT CTT TTT ACC ATC CCC TTT GAC<br>105 110 115 120 | 360 |
| 20 | TGC TGG GGG CCA GTC AAA AAG<br>Cys Trp Gly Pro Val Lys Lys<br>125                  |     |

25 6. Polynukleotid gemäß Anspruch 5, umfassend die folgende Sequenz:

|    |  |     |
|----|--|-----|
| 30 | GCT CCC ACC CGC CCA CCC AGC CCT<br>1 5   | 24  |
|    | GTC ACC CGG CCC TGG CAG CAT GTG GAT GCC ATC AAA GAA GCC CTG AGC<br>10 15 20  | 72  |
| 35 | CTT CTA AAC AAC AGT AAT GAC ACA GCG GCT GTG ATG AAT GAA ACC GTA<br>25 30 35 40   | 120 |
|    | GAC GTC GTC TGT GAA ATG TTT GAC CCC CAG GAG CCG ACA TGC GTG CAG<br>45 50 55  | 168 |
| 40 | ACT CGC CTG AAC CTG TAC AAG CAG GGC CTG CGG GGC AGC CTC ACT AGG<br>60 65 70  | 216 |
|    | CTC AAG AGC CCC TTG ACT CTG TTG GCC AAG CAC TAT GAG CAG CAC TGC<br>Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys<br>75 80 85 | 264 |
| 45 | CCC CTC ACC GAG GAA ACT TCC TGT GAA ACC CAG TCT ATC ACC TTC AAA<br>90 95 100   | 312 |
| 50 | AGT TTC AAA GAC AGT CTG AAC AAA TTT CTT TTT ACC ATC CCC TTT GAC<br>105 110 115 120   | 360 |
| 55 | TGC TGG GGG CCA GTC AAA AAG<br>125   |     |

7. Polynukleotid, umfassend (a) eine Polynukleotidsequenz, die zu wenigstens 90 % identisch zu einem Polynukleotid

ist, das für ein Polypeptid kodiert, welches die folgenden Aminosäuren umfasst:

| 5  | Met Pro Thr   |     |     |     |
|----|---|-----|-----|-----|
|    | 1   |     |     |     |
| 10 | Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr | 5   | 10  | 15  |
|    | Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu | 20  | 25  | 30  |
| 15 | Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu | 40  | 45  | 50  |
|    | Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly | 55  | 60  | 65  |
| 20 | Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met | 70  | 75  | 80  |
|    | Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe | 85  | 90  | 95  |
| 25 | Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys | 100 | 105 | 110 |
|    | Pro Met Ile Thr Glu Pro   | 120 |     | 115 |

oder  
(b) das Komplement von (a).

35 8. Polynukleotid gemäß Anspruch 7, kodierend für ein Polypeptid, das die folgenden Aminosäuren umfasst:

45

50

55

|    |   |     | Met | Pro | Thr |
|----|---|-----|-----|-----|-----|
|    |   |     | 1   |     |     |
| 5  | Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr |     |     |     |     |
|    | 5   | 10  | 15  |     |     |
|    | Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu |     |     |     |     |
| 10 | 20  | 25  | 30  | 35  |     |
|    | Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu |     |     |     |     |
|    | 40  | 45  | 50  |     |     |
| 15 | Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly |     |     |     |     |
|    | 55  | 60  | 65  |     |     |
|    | Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met |     |     |     |     |
|    | 70  | 75  | 80  |     |     |
| 20 | Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe |     |     |     |     |
|    | 85  | 90  | 95  |     |     |
|    | Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys |     |     |     |     |
| 30 | 100   | 105 | 110 | 115 |     |
| 25 | Pro Met Ile Thr Glu Pro   |     |     |     |     |
|    | 120   |     |     |     |     |

9. Polynucleotid gemäß Anspruch 7, umfassend eine Polynucleotidsequenz, die zu wenigstens 90 % identisch zu einem Polynucleotid ist, welches die folgende Sequenz umfasst:

|    |   |    | ATG | CCT | ACC | 9   |
|----|---|----|-----|-----|-----|-----|
| 35 |   |    | 1   |     |     |     |
|    | ACA ACA CTC CAA CCT AAA AAC TAC CTT GCC ATG ATC CAG GAA ATT ACA |    |     |     |     | 57  |
|    | 5   | 10 | 15  |     |     |     |
| 40 | AGA AGC CTA GAG AAC CTA ACT GTG ACT TCA AAT AAA TCC TTG ACG TTG |    |     |     |     | 105 |
|    | 20  | 25 | 30  | 35  |     |     |
|    | AAT GAG CTC GAA ACC CTG GTG AAT AAC ACT CTT CTG AGA CCA AAC CTG |    |     |     |     | 153 |
|    | 40  | 45 | 50  |     |     |     |
| 45 | GAA GCA TTC GTG ACA TTT GCT GAA AAC CAC TTA AAA AAT ATT TCA GGA |    |     |     |     | 201 |
|    | 55  | 60 | 65  |     |     |     |

50

55

|    |   |     |
|----|---|-----|
|    | ATC AAG AAA AAC CTT GAG AAA TTC CGG CCA ATC CTG CCC ACG TCT ATG | 249 |
|    | 70 75 80  |     |
| 5  | TCC ACG GAA GAG CCA ATC TCT ATT GAG GAG GGC GAC CTT GGT GAT TTC | 297 |
|    | 85 90 95  |     |
|    | CGG GCG AAA CTG ATG GAG TAT CTG GTT GTC CTT AGA GAC TCT CTG AAA | 345 |
| 10 | 100 105 110 115   |     |
|    | CCC ATG ATC ACA GAG CCC   | 396 |
|    | 120   |     |

15 10. Polynucleotid gemäß Anspruch 2, das die folgende Sequenz aufweist:

|    |   |     |
|----|---|-----|
|    | GCCTTTCCTT  | 15  |
| 20 | ATG AAG AAG ACA CAA ACT TGG ATT ATC ACT TGC ATT TAT CTT CAA CTG | 63  |
|    | Met Lys Lys Thr Gln Thr Trp Ile Ile Thr Cys Ile Tyr Leu Gln Leu |     |
|    | -25. -20 -15 -10  |     |
| 25 | CTC CTA TTT AAT CCT CTC GTC AGA ACT CAA GGG ATC TGC AGG AAC CGT | 111 |
|    | Leu Leu Phe Asn Pro Leu Val Arg Thr Gln Gly Ile Cys Arg Asn Arg |     |
|    | -5 1 5  |     |
| 30 | GTG ACT GAT GAT GTG AAA GAC GTT ACA AAA TTG GTG GCA AAT CTT CCA | 159 |
|    | Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro |     |
|    | 10 15 20  |     |
|    | AAA GAC TAT AAG ATA ACC CTC AAA TAT GTC CCC GGG ATG GAC GTT TTG | 207 |
|    | Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu |     |
| 35 | 25 30 35  |     |
|    | CCT AGT CAT TGT TGG ATA AGC GAA ATG GTG GAA CAA CTG TCA GTC AGC | 255 |
| 40 | Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser |     |
|    | 40 45 50 55   |     |
|    | TTG ACT GAT CTT CTG GAC AAG TTT TCC AAT ATT TCT GAA GGC TTG AGT | 303 |
|    | Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser |     |
| 45 | 60 65 70  |     |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | AAT TAT TCT ATC ATA GAC AAA CTT GTG AAA ATT GTT GAT GAC CTC GTG | 351 |     |     |
|    | Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val |     |     |     |
| 5  | 75  | 80  | 85  |     |
|    | GAA TGC ATG GAA GAA CAC TCA TTT GAG AAT GTA AGA AAA TCA TCT AAG | 399 |     |     |
|    | Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys |     |     |     |
| 10 | 90  | 95  | 100 |     |
|    | AGC CCA GAA CCC AGG CTG TTT ACT CCT GAA AAA TTC TTT GGG ATT TTT | 447 |     |     |
|    | Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe |     |     |     |
|    | 105   | 110 | 115 |     |
| 15 | AAT AGA TCC ATC GAT GCC TTC AAG GAT TTG GAG ATG GTG GCA CCT AAA | 495 |     |     |
|    | Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys |     |     |     |
|    | 120   | 125 | 130 | 135 |
| 20 | ACT AGT GAA TGT GTG ATT TCT TCA ACA TTA ACT CCT GAA AAA GAT TCC | 543 |     |     |
|    | Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser |     |     |     |
|    | 140   | 145 | 150 |     |
| 25 | AGA GTC AGT GTC ACA AAA CCA TTT ATG TTA CCC CCT GTT GCA GCC AGC | 591 |     |     |
|    | Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser |     |     |     |
|    | 155   | 160 | 165 |     |
|    | TCC CTT AGG AAT GAC AGC AGT AGC AGT AAT AGG AAA GCC TAA         | 633 |     |     |
| 30 | Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala                 |     |     |     |
|    | 170   | 175 | 180 |     |

11. Expressionsvektor, umfassend das Polynukleotid gemäß Anspruch 1 und eine zur Unterstützung der Transkription des Polynukleotids wirksame Regulationssequenz.

35 12. Expressionsvektor, umfassend das Polynukleotid gemäß Anspruch 3 und eine zur Unterstützung der Transkription des Polynukleotids wirksame Regulationssequenz.

40 13. Expressionsvektor, umfassend das Polynukleotid gemäß Anspruch 7 und eine zur Unterstützung der Transkription des Polynukleotids wirksame Regulationssequenz.

45 14. Expressionsvektor gemäß Anspruch 11, der weiterhin eine Kodierungssequenz für wenigstens ein zusätzliches Cytokin und eine Transkriptionsregulationssequenz dafür umfasst.

15. Expressionsvektor gemäß Anspruch 12, der weiterhin eine Kodierungssequenz für wenigstens ein zusätzliches Cytokin und eine Transkriptionsregulationssequenz dafür umfasst.

50 16. Isolierte Schwein-Knochenmarkszellen, die einen Expressionsvektor enthalten, der das Polynukleotid gemäß Anspruch 1 umfasst.

17. Isolierte Schwein-Knochenmarkszellen, die einen Expressionsvektor enthalten, der das Polynukleotid gemäß Anspruch 3 umfasst.

55 18. Isolierte Schwein-Knochenmarkszellen, die einen Expressionsvektor enthalten, der das Polynukleotid gemäß Anspruch 7 umfasst.

19. Expressionsvektor, umfassend das Polynukleotid gemäß Anspruch 2.

20. Expressionsvektor, umfassend das Polynucleotid gemäß Anspruch 4.

21. Expressionsvektor, umfassend das Polynucleotid gemäß Anspruch 8.

5 22. Polynucleotid gemäß Anspruch 9, umfassend die Sequenz:

|    |  |             |     |
|----|--|-------------|-----|
|    |  | ATG CCT ACC | 101 |
| 10 |  | 1           |     |
|    | ACA ACA CTC CAA CCT AAA AAC TAC CTT GCC ATG ATC CAG GAA ATT ACA    |             | 149 |
|    | 5  | 10          | 15  |
|    | AGA AGC CTA GAG AAC CTA ACT GTG ACT TCA AAT AAA TCC TTG ACG TTG    |             | 197 |
| 15 | 20   | 25          | 30  |
|    |  |             | 35  |
| 20 | AAT GAG CTC GAA ACC CTG GTG AAT AAC ACT CTT CTG AGA CCA AAC CTG    |             | 245 |
|    | 40   | 45          | 50  |
|    | GAA GCA TTC GTG ACA TTT GCT GAA AAC CAC TTA AAA AAT ATT TCA GGA    |             | 293 |
|    | 55   | 60          | 65  |
| 25 | ATC AAG AAA AAC CTT GAG AAA TTC CGG CCA ATC CTG CCC ACG TCT ATG    |             | 341 |
|    | 70   | 75          | 80  |
|    | TCC ACG GAA GAG CCA ATC TCT ATT GAG GAG GGC GAC CTT GGT GAT TTC    |             | 389 |
| 30 | 85   | 90          | 95  |
|    | CGG GCG AAA CTG ATG GAG TAT CTG GTT GTC CTT AGA GAC TCT CTG AAA    |             | 437 |
|    | 100  | 105         | 110 |
|    | 115  |             |     |
|    | CCC ATG ATC ACA GAG CCC TAA AATCTGAAGT GTGAACCTCCA GCTCTCTCTC      |             | 488 |
| 35 | 120  |             |     |
|    | TGGAGCCCTG GAACGTCAGG AACAGCAGAT CGTCCTAAGA TGGCGTGGACC GTCTCTCACA |             | 548 |
|    | CCATCCAGGA CTGACGTTT CTCCCTGTGGA GTCTGTTGAA TTGTTAACTA TCTAATCCCT  |             | 608 |
| 40 | GAAATGTGCA GCCCCATTG TCCTTTGCG ATTAGGTTCT CATTCTTATT GTATTGAGGC    |             | 668 |
|    | TATTTATTAA TGTATGTATT TATTTATTAT CTTGTGCAAT GTGAAATGTA TTTACTTAAC  |             | 728 |
|    | AGAGAAGCCA TGGCCTGCTC CTTCTGAATG AG                                |             | 760 |

45 23. Polypeptid, umfassend eine Polypeptidsequenz, die zu wenigstens 90 % identisch zu einem Polypeptid ist, das die folgende Aminosäuresequenz umfasst:

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    |     |     | Gln | Gly | Ile | Cys | Arg | Asn | Arg |     |     |     |     |     |     |     |
|    |     |     | 1   |     |     |     | 5   |     |     |     |     |     |     |     |     |     |
| 5  | Val | Thr | Asp | Asp | Val | Lys | Asp | Val | Thr | Lys | Leu | Val | Ala | Asn | Leu | Pro |
|    |     |     | 10  |     |     |     | 15  |     |     |     |     |     |     | 20  |     |     |
| 10 | Lys | Asp | Tyr | Lys | Ile | Thr | Leu | Lys | Tyr | Val | Pro | Gly | Met | Asp | Val | Leu |
|    |     |     | 25  |     |     |     | 30  |     |     |     |     |     | 35  |     |     |     |
| 15 | Pro | Ser | His | Cys | Trp | Ile | Ser | Glu | Met | Val | Glu | Gln | Leu | Ser | Val | Ser |
|    |     |     | 40  |     |     |     | 45  |     |     |     | 50  |     |     | 55  |     |     |
| 20 | Leu | Thr | Asp | Leu | Leu | Asp | Lys | Phe | Ser | Asn | Ile | Ser | Glu | Gly | Leu | Ser |
|    |     |     | 60  |     |     |     | 65  |     |     |     | 70  |     |     |     |     |     |
| 25 | Asn | Tyr | Ser | Ile | Ile | Asp | Lys | Leu | Val | Lys | Ile | Val | Asp | Asp | Leu | Val |
|    |     |     | 75  |     |     |     | 80  |     |     |     | 85  |     |     |     |     |     |
| 30 | Glu | Cys | Met | Glu | Glu | His | Ser | Phe | Glu | Asn | Val | Arg | Lys | Ser | Ser | Lys |
|    |     |     | 90  |     |     |     | 95  |     |     |     |     |     | 100 |     |     |     |
| 35 | Ser | Pro | Glu | Pro | Arg | Leu | Phe | Thr | Pro | Glu | Lys | Phe | Phe | Gly | Ile | Phe |
|    |     |     | 105 |     |     |     | 110 |     |     |     |     |     | 115 |     |     |     |
| 40 | Asn | Arg | Ser | Ile | Asp | Ala | Phe | Lys | Asp | Leu | Glu | Met | Val | Ala | Pro | Lys |
|    |     |     | 120 |     |     |     | 125 |     |     |     | 130 |     |     | 135 |     |     |
| 45 | Thr | Ser | Glu | Cys | Val | Ile | Ser | Ser | Thr | Leu | Thr | Pro | Glu | Lys | Asp | Ser |
|    |     |     | 140 |     |     |     | 145 |     |     |     |     |     | 150 |     |     |     |
| 50 | Arg | Val | Ser | Val | Thr | Lys | Pro | Phe | Met | Leu | Pro | Pro | Val | Ala | Ala | Ser |
|    |     |     | 155 |     |     |     | 160 |     |     |     |     |     | 165 |     |     |     |
| 55 | Ser | Leu | Arg | Asn | Asp | Ser | Ser | Ser | Ser | Asn | Arg | Lys | Ala |     |     |     |
|    |     |     | 170 |     |     |     | 175 |     |     |     |     |     | 180 |     |     |     |

24. Polypeptid gemäß Anspruch 23, umfassend die folgenden Aminosäuren:

45

50

55

| Gln Gly Ile Cys Arg Asn Arg |   |     |     |
|-----------------------------|---|-----|-----|
|                             | 1   | 5   |     |
| 5                           | Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro |     |     |
|                             | 10  | 15  | 20  |
|                             | Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu |     |     |
| 10                          | 25  | 30  | 35  |
|                             | Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser |     |     |
|                             | 40  | 45  | 50  |
| 15                          | Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser |     |     |
|                             | 60  | 65  | 70  |
|                             | Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val |     |     |
|                             | 75  | 80  | 85  |
| 20                          | Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys |     |     |
|                             | 90  | 95  | 100 |
|                             | Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe |     |     |
|                             | 105   | 110 | 115 |
| 25                          | Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys |     |     |
|                             | 120   | 125 | 130 |
| 30                          | Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser |     |     |
|                             | 140   | 145 | 150 |
|                             | Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser |     |     |
| 35                          | 155   | 160 | 165 |
|                             | Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala                 |     |     |
|                             | 170   | 175 | 180 |

40 25. Polypeptid, umfassend eine Polypeptidsequenz, die zu wenigstens 90 % zu einem Polypeptid identisch ist, das die folgende Aminosäuresequenz umfasst:

45

50

55

|    |   |     |                                 |
|----|---|-----|---------------------------------|
|    |   |     | Ala Pro Thr Arg Pro Pro Ser Pro |
|    |   | 1   | 5                               |
| 5  | Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser |     |                                 |
|    | 10  | 15  | 20                              |
|    | Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val |     |                                 |
| 10 | 25  | 30  | 35                              |
|    |   |     | 40                              |
|    | Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln |     |                                 |
|    | 45  | 50  | 55                              |
| 15 | Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg |     |                                 |
|    | 60  | 65  | 70                              |
|    | Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys |     |                                 |
| 20 | 75  | 80  | 85                              |
|    | Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys |     |                                 |
|    | 90  | 95  | 100                             |
|    | Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp |     |                                 |
| 25 | 105   | 110 | 115                             |
|    | Cys Trp Gly Pro Val Lys Lys                                     |     |                                 |
|    | 125   |     |                                 |

30 26. Polypeptid gemäß Anspruch 25, umfassend die folgenden Aminosäuren:

35

40

45

50

55

Ala Pro Thr Arg Pro Pro Ser Pro  
1 5

5 Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser  
10 15 20

Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val  
10 25 30 35 40

Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln  
15 45 50 55

Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg  
20 60 65 70

Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys  
25 75 80 85

Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys  
90 95 100

Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp  
105 110 115 120

Cys Trp Gly Pro Val Lys Lys  
125

30 27. Polypeptid, umfassend eine Sequenz, die zu wenigstens 90 % zu einem Polypeptid identisch ist, das die folgende Aminosäuresequenz umfasst:

Met Pro Thr  
35 1

Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr  
40 5 10 15

Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu  
45 20 25 30 35

50

55

Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu  
 40 45 50  
 5 Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly  
 55 60 65  
 Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met  
 70 75 80  
 10 Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe  
 85 90 95  
 Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys  
 100 105 110 115  
 15 Pro Met Ile Thr Glu Pro  
 120

20 28. Polypeptid gemäß Anspruch 27, umfassend die folgenden Aminosäuren:

Met Pro Thr  
 1  
 25 Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr  
 5 10 15  
 Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu  
 30 20 25 30 35  
 Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu  
 40 45 50  
 Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly  
 35 55 60 65  
 Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met  
 70 75 80  
 40 Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe  
 85 90 95  
 Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys  
 100 105 110 115  
 45 Pro Met Ile Thr Glu Pro  
 120

50 29. Verwendung von einem oder mehreren Polypeptiden gemäß einem der Ansprüche 23 bis 28 zur Herstellung einer Zusammensetzung zur Förderung der Transplantation von Schwein-Knochenmarkszellen in einem xenogenen Empfänger.

55 30. Verwendung von einem oder mehreren Polynucleotiden gemäß einem der Ansprüche 1 bis 10 zur Herstellung einer Zusammensetzung zur Förderung der Transplantation von Schwein-Knochenmarkszellen in einem xenogenen Empfänger.

## Revendications

1. Un poly-nucléotide comprenant (a) une séquence de poly-nucléotide qui encode un polypeptide comprenant les aminoacides suivants :

5

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    |     | Gln | Gly | Ile | Cys | Arg | Asn | Arg |     |     |     |     |     |     |     |     |
|    |     | 1   |     |     |     | 5   |     |     |     |     |     |     |     |     |     |     |
| 10 | Val | Thr | Asp | Asp | Val | Lys | Asp | Val | Thr | Lys | Leu | Val | Ala | Asn | Leu | Pro |
|    | 10  |     |     |     | 15  |     |     | 20  |     |     |     |     |     |     |     |     |
| 15 | Lys | Asp | Tyr | Lys | Ile | Thr | Leu | Lys | Tyr | Val | Pro | Gly | Met | Asp | Val | Leu |
|    | 25  |     |     |     | 30  |     |     | 35  |     |     |     |     |     |     |     |     |
| 20 | Pro | Ser | His | Cys | Trp | Ile | Ser | Glu | Met | Val | Glu | Gln | Leu | Ser | Val | Ser |
|    | 40  |     |     |     | 45  |     |     | 50  |     |     | 55  |     |     |     |     |     |
| 25 | Leu | Thr | Asp | Leu | Leu | Asp | Lys | Phe | Ser | Asn | Ile | Ser | Glu | Fly | Leu | Ser |
|    | 60  |     |     |     | 65  |     |     | 70  |     |     |     |     |     |     |     |     |
| 30 | Asn | Tyr | Ser | Ile | Ile | Asp | Lys | Leu | Val | Lys | Ile | Val | Asp | Asp | Leu | Val |
|    | 75  |     |     |     | 80  |     |     | 85  |     |     |     |     |     |     |     |     |
| 35 | Glu | Cys | Met | Glu | Glu | His | Ser | Phe | Glu | Asn | Val | Arg | Lys | Ser | Ser | Lys |
|    | 90  |     |     |     | 95  |     |     | 100 |     |     |     |     |     |     |     |     |
| 40 | Ser | Pro | Glu | Pro | Arg | Leu | Phe | Thr | Pro | Glu | Lys | Phe | Phe | Gly | Ile | Phe |
|    | 105 |     |     |     | 110 |     |     | 115 |     |     |     |     |     |     |     |     |
| 45 | Asn | Arg | Ser | Ile | Asp | Ala | Phe | Lys | Asp | Leu | Glu | Met | Val | Ala | Pro | Lys |
|    | 120 |     |     |     | 125 |     |     | 130 |     |     | 135 |     |     |     |     |     |
| 50 | Thr | Ser | Glu | Cys | Val | Ile | Ser | Ser | Thr | Leu | Thr | Pro | Glu | Lys | Asp | Ser |
|    | 140 |     |     |     | 145 |     |     | 150 |     |     |     |     |     |     |     |     |
| 55 | Arg | Val | Ser | Val | Thr | Lys | Pro | Phe | Met | Leu | Pro | Pro | Val | Ala | Ala | Ser |
|    | 155 |     |     |     | 160 |     |     | 165 |     |     |     |     |     |     |     |     |
| 60 | Ser | Leu | Arg | Asn | Asp | Ser | Ser | Ser | Asn | Arg | Lys | Ala |     |     |     |     |
|    | 170 |     |     |     | 175 |     |     | 180 |     |     |     |     |     |     |     |     |

45

ou

(b) le complément de (a).

50

2. Le poly-nucléotide de la revendication 1, dans lequel la séquence de poly-nucléotide encode ledit polypeptide.

55

3. Un poly-nucléotide comprenant un poly-nucléotide sélectionné dans le groupe constitué par :

(a) une séquence de poly-nucléotides qui est pour au moins à 90% identique à un poly-nucléotide encodant un polypeptide comprenant la séquence d'aminoacides suivante :

55

4. Un poly-nucléotide selon la revendication 3, dans lequel le poly-nucléotide encode un polypeptide comprenant les aminoacides suivants :

|     | Ala | Pro | Thr | Arg | Pro | Pro | Ser | Pro |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|     | 1   |     |     |     |     |     | 5   |     |     |     |     |     |     |     |     |
| Val | Thr | Arg | Pro | Trp | Gln | His | Val | Asp | Ala | Ile | Lys | Glu | Ala | Leu | Ser |
| 10  |     |     |     |     |     |     | 15  |     |     |     |     | 20  |     |     |     |
| Leu | Leu | Asn | Asn | Ser | Asn | Asp | Thr | Ala | Ala | Val | Met | Asn | Glu | Thr | Val |
| 25  |     |     |     |     |     |     | 30  |     |     |     | 35  |     |     | 40  |     |
| Asp | Val | Val | Cys | Glu | Met | Phe | Asp | Pro | Gln | Glu | Pro | Thr | Cys | Val | Gln |
|     |     |     |     |     |     |     | 45  |     |     |     | 50  |     |     | 55  |     |
| Thr | Arg | Leu | Asn | Leu | Tyr | Lys | Gln | Gly | Leu | Arg | Gly | Ser | Leu | Thr | Arg |
| 60  |     |     |     |     |     |     | 65  |     |     |     |     | 70  |     |     |     |

Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys  
 75 80 85  
 5 Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys  
 90 95 100  
 Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp  
 10 105 110 115 120  
 10 Cys Trp Gly Pro Val Lys Lys  
 125

15 5. Un poly-nucléotide selon la revendication 3, dans lequel la séquence de poly-nucléotide est pour au moins à 90% identique à un poly-nucléotide comprenant la séquence suivante :

20 GCT CCC ACC CGC CCA CCC AGC CCT 24  
 1 5  
 GTC ACC CGC CCC TGG CAG CAT GTG GAT GCC ATC AAA GAA GCC AGC 72  
 10 15 20  
 25 CTT CTA AAC AAC AGT AAT GAC ACA GCG GCT GTG ATG AAT GGA ACC GTA 120  
 25 30 35 40  
 GAC GTC GTC TGT GAA ATG TTT GAC CCC CAG GAG CCG ACA TGC GTG CAG 168  
 30 45 50 55  
 ACT CGC CTG AAC CTG TAC AAG CAG GGC CTG CGG GGC AGC CTC ACT AGG 216  
 60 65 70  
 35 CTC AAG AGC CCC TTG ACT CTG TTG GCC AAG CAC TAT GAG CAG CAC TGC 264  
 75 80 85  
 CCC CTC ACC GAG GAA ACT TCC TGT GAA ACC CAG TCT ATC ACC TTC AAA 312  
 90 95 100  
 40 AGT TTC AAA GAC AGT CTG AAC AAA TTT CTT TTT ACC ATC CCC TTT GAC 360  
 105 110 115 120  
 TGC TGG GGG CCA GTC AAA AAG  
 45 Cys Trp Gly Pro Val Lys Lys  
 125

50 6. Le poly-nucléotide selon la revendication 5, comprenant la séquence suivante:

GCT CCC ACC CGC CCA CCC AGC CGT 24  
 1 5

|    |   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | GTC ACC CGG CCC TGG CAG CAT GTG GAT GCC ATC AAA GAA GCC CTG AGC |     |     |     | 72  |     |     |     |     |     |     |     |     |     |     |     |
|    | 10  | 15  | 20  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 5  | CTT CTA AAC AAC AGT AAT GAC ACA GCG GCT GTG ATG AAT GAA ACC GTA |     |     |     | 120 |     |     |     |     |     |     |     |     |     |     |     |
|    | 25  | 30  | 35  | 40  | :   |     |     |     |     |     |     |     |     |     |     |     |
|    | GAC GTC GTC TGT GAA ATG TTT GAC CCC CAG GAG CCG ACA TGC GTG CAG |     |     |     | 168 |     |     |     |     |     |     |     |     |     |     |     |
| 10 | 45  | 50  | 55  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | ACT CGC CTG AAC CTG TAC AAG CAG GGC CTG CGG GGC AGC CTC ACT AGG |     |     |     | 216 |     |     |     |     |     |     |     |     |     |     |     |
|    | 60  | 65  | 70  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 15 | CTC AAG AGC CCC TTG ACT CTG TTG GCC AAG CAC TAT GAG CAG CAC TGC |     |     |     | 264 |     |     |     |     |     |     |     |     |     |     |     |
|    | Leu   | Lys | Ser | Pro | Leu | Thr | Leu | Leu | Ala | Lys | His | Tyr | Glu | Gln | His | Cys |
|    | 75  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 20 | CCC CTC ACC GAG GAA ACT TCC TGT GAA ACC CAG TCT ATC ACC TTC AAA |     |     |     | 312 |     |     |     |     |     |     |     |     |     |     |     |
|    | 90  | 95  | 100 |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | AGT TTC AAA GAC AGT CTG AAC AAA TTT CTT TTT ACC ATC CCC TTT GAC |     |     |     | 360 |     |     |     |     |     |     |     |     |     |     |     |
| 25 | 105   | 110 | 115 | 120 |     |     |     |     |     |     |     |     |     |     |     |     |
|    | TGC TGG GGG CCA GTC AAA AAG                                     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | 125   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

30 7. Un poly-nucléotide comprenant (a) une séquence de poly-nucléotide qui est pour au moins à 90% identique à un poly-nucléotide qui encode un polypeptide comprenant les aminoacides suivants :

|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Met Pro Thr |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 35 |             | 1   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Thr         | Thr | Leu | Gln | Pro | Lys | Asn | Tyr | Leu | Ala | Met | Ile | Gln | Glu | Ile | Thr |  |
|    | 5           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 40 | Arg         | Ser | Leu | Glu | Asn | Leu | Thr | Val | Thr | Ser | Asn | Lys | Ser | Leu | Thr | Leu |  |
|    | 20          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Asn         | Glu | Leu | Glu | Thr | Leu | Val | Asn | Asn | Thr | Leu | Leu | Arg | Pro | Asn | Leu |  |
|    | 40          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 45 | Glu         | Ala | Phe | Val | Thr | Phe | Ala | Glu | Asn | His | Leu | Lys | Asn | Ile | Ser | Gly |  |
|    | 55          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 50 | Ile         | Lys | Lys | Asn | Leu | Glu | Lys | Phe | Arg | Pro | Ile | Leu | Pro | Thr | Ser | Met |  |
|    | 70          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Ser         | Thr | Glu | Glu | Pro | Ile | Ser | Ile | Glu | Glu | Gly | Asp | Leu | Gly | Asp | Phe |  |
|    | 85          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 55 | Arg         | Ala | Lys | Leu | Met | Glu | Tyr | Leu | Val | Val | Leu | Arg | Asp | Ser | Leu | Lys |  |
|    | 100         |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | 105         |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | 110         |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | 115         |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |

Pro Met Ile Thr Glu Pro  
120

5

ou

(b) le complément de (a).

8. Poly-nucléotide selon la revendication 7 encodant un polypeptide comprenant les aminoacides suivants :  
10

Met Pro Thr  
1

15

Thr Thr Leu Gin Pro Lys Asn Tyr Leu Ala Met Ile Gin Glu Ile Thr  
5 10 15

20

Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu  
20 25 30 35

Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu  
40 45 50

25

Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly  
55 60 65

30

Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met  
70 75 80

35

Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe  
85 90 95

40

Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys  
100 105 110 115

Pro Met Ile Thr Glu Pro

120

9. Le poly-nucléotide de la revendication 7 comprenant une séquence de poly-nucléotides qui est pour au moins à 90% identique à un poly-nucléotide comprenant la séquence suivante :

ATG CCT ACC 9  
45 1

ACA ACA CTC CAA CCT AAA AAC TAC CTT GCC ATG ATC CAG GAA ATT ACA 57

5 10 15

50

AGA AGC CTA GAG AAC CTA ACT GTG ACT TCA AAT AAA TCC TTG ACG TTG 105

20 25 30 35

AAT GAG CTC GAA ACC CTG GTG AAT AAC ACT CTT CTG AGA CCA AAC CTG 153

55

40 45 50

GAA GCA TTC GTG ACA TTT GCT GAA AAC CAC TTA AAA AAT ATT TCA GGA 201  
5 55 60 65  
ATC AAG AAA AAC CTT GAG AAA TTC CGG CCA ATC CTG CCC ACG TCT ATG 249  
70 75 80  
TCC ACG GAA GAG CCA ATC TCT ATT GAG GAG GGC GAC CTT GGT GAT TTC 297  
10 85 90 95  
CGG GCG AAA CTG ATG GAG TAT CTG GTT GTC CTT AGA GAC TCT CTG AAA 345  
100 105 110 115  
15 CCC ATG ATC ACA GAG CCC 396  
120

10. Le poly-nucléotide de la revendication 2 ayant la séquence suivante :

20

25

30

35

40

45

50

55

|    |   |     |
|----|---|-----|
|    | GCGCT GCCTTCCTT   | 15  |
| 5  | ATG AAG AAG ACA CAA ACT TGG ATT ATC ACT TGC ATT TAT CTT CAA CTG | 63  |
|    | Met Lys Lys The Gln Thr Trp Ile Ile Thr Cys Ile Tyr Leu Gln Leu |     |
|    | -25 -20 -15 -10   |     |
|    | CTC CTA TTT AAT CCT CTC GTC AGA ACT CAA GGG ATC TGC AGG AAC CGT | 111 |
| 10 | Leu Leu Phe Asn Pro Leu Val Arg Thr Gln Gly Ile Cys Arg Asn Arg |     |
|    | -5 1 5  |     |
|    | GTG ACT GAT GAT GTG AAA GAC GTT ACA AAA TTG GTG GCA AAT CTT CCA | 159 |
| 15 | Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro |     |
|    | 10 15 20  |     |
|    | AAA GAC TAT AAG ATA ACC CTC AAA TAT GTC CCC GGG ATG GAC GTT TTG | 207 |
| 20 | Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu |     |
|    | 25 30 35  |     |
|    | CCT AGT CAT TGT TGG ATA AGC GAA ATG GTG GAA CAA CTG TCA GTC AGC | 255 |
| 25 | Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser |     |
|    | 40 45 50 55   |     |
|    | TTG ACT GAT CTT CTG GAC AAG TTT TCC AAT ATT TCT GAA GGC TTG AGT | 303 |
|    | Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser |     |
| 30 | 60 65 70  |     |
|    | AAT TAT TCT ATC ATA GAC AAA CTT GTG AAA ATT GTT GAT GAC CTC GTG | 351 |
|    | Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val |     |
| 35 | 75 80 85  |     |
|    | GAA TGC ATG GAA GAA CAC TCA TTT GAG AAT GTA AGA AAA TCA TCT AAG | 399 |
|    | Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys |     |
| 40 | 90 95 100   |     |

45

50

55

|    |   |     |
|----|---|-----|
|    | AGC CCA GAA CCC AGG CTG TTT ACT CCT GAA AAA TTC TTT GGG ATT TTT | 447 |
| 5  | Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe |     |
|    | 105 110 115   |     |
|    | AAT AGA TCC ATC GAT GCC TTC AAG GAT TTG GAG ATG GTG GCA CCT AAA | 495 |
|    | Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys |     |
| 10 | 120 125 130 135   |     |
|    | ACT AGT GAA TGT GTG ATT TCT TCA ACA TTA ACT CCT GAA AAA GAT TTC | 543 |
|    | Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser |     |
| 15 | 140 145 150   |     |
|    | AGA GTC AGT GTC ACA AAA CCA TTT ATG TTA CCC CCT GTT GCA GCC AGC | 591 |
|    | Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser |     |
| 20 | 155 160 165   |     |
|    | TCC CTT AGG AAT GAC AGC AGT AGC AGT AAT AGG AAA GCC TAA         | 633 |
|    | Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala                 |     |
| 25 | 170 175 180   |     |

11. Un vecteur d'expression comprenant le poly-nucléotide de la revendication 1 et une séquence régulatrice ayant pour effet d'en supporter la transcription.

30 12. Un vecteur d'expression comprenant le poly-nucléotide de la revendication 3 et une séquence régulatrice ayant pour effet d'en supporter la transcription.

13. Un vecteur d'expression comprenant le poly-nucléotide de la revendication 7 et une séquence régulatrice ayant pour effet d'en supporter la transcription.

35 14. Le vecteur d'expression de la revendication 11, comprenant au surplus une séquence encodante pour au moins une cytokine additionnelle et une séquence régulatrice de transcription pour celle-ci.

15. Le vecteur d'expression de la revendication 12, comprenant au surplus une séquence encodante pour au moins une cytokine additionnelle et une séquence régulatrice de transcription de celle-ci.

40 16. Des cellules isolées de moelle osseuse porcine, qui contiennent un vecteur d'expression comprenant le poly-nucléotide de la revendication 1.

17. Des cellules isolées de moelle osseuse porcine, qui contiennent un vecteur d'expression comprenant le poly-nucléotide de la revendication 3.

45 18. Des cellules isolées de moelle osseuse porcine, qui contiennent un vecteur d'expression comprenant le poly-nucléotide de la revendication 7.

19. Un vecteur d'expression comprenant le poly-nucléotide de la revendication 2.

50 20. Un vecteur d'expression comprenant le poly-nucléotide de la revendication 4.

21. Un vecteur d'expression comprenant le poly-nucléotide de la revendication 8.

55 22. Le poly-nucléotide de la revendication 9 comprenant la séquence :

|    |   |     |
|----|---|-----|
|    | ATG CCT ACC   | 101 |
|    | 1   |     |
| 5  | ACA ACA CTC CAA CCT AAA AAC TAC CTT GCC ATG ATC CAG GAA ATT ACA   | 149 |
|    | 5 10 15   |     |
|    | AGA AGC CTA GAG AAC CTA ACT GTG ACT TCA AAT AAA TCC TTG ACG TTG   | 197 |
| 10 | 20 25 30 35   |     |
|    | AAT GAG CTC GAA ACC CTG GTG AAT AAC ACT CTT CTG AGA CCA AAC CTG   | 245 |
|    | 40 45 50  |     |
|    | GAA GCA TTC GTG ACA TTT GCT GAA AAC CAC TTA AAA AAT ATT TCA GGA   | 293 |
| 15 | 55 60 65  |     |
|    | ATC AAG AAA AAC CTT GAG AAA TTC CGG CCA ATC CTG CCC ACG TCT ATG   | 341 |
|    | 70 75 80  |     |
| 20 | TCC ACG GAA GAG CCA ATC TCT ATT GAG GAG GGC GAC CTT GGT GAT TTC   | 389 |
|    | 85 90 95  |     |
|    | CGG GCG AAA CTG ATG GAG TAT CTG GTT GTC CTT AGA GAC TCT CTG AAA   | 437 |
| 25 | 100 105 110 115   |     |
|    | CCC ATG ATC ACA GAG CCC TAA AATCTGAAGT GTGAACCTCCA GCTCTCTCTC     | 488 |
|    | 120   |     |
| 30 | TGGAGCCCTG GAACGTCAGG AACAGCAGAT CGTCCTAAGA TGCGTGGACC GTCTCTCACA | 548 |
|    | CCATCCAGGA CTGACGTTT CTCCTGTGGA GTCTGTTGAA TTGTTAACTA TCTAATCCCT  | 608 |
|    | GAAATGTGCA GCCCCATTG TCCTTTGCG ATTAGGTTCT CATTCTTATT GTATTGAGGC   | 668 |
| 35 |   |     |
|    | TATTTATTTA TGTATGTATT TATTTATTAT CTTGTGCAAT GTGAAATGTA TTTACTAAC  | 728 |
|    | AGAGAAGCCA TGGCCTGCTC CTTCTGAATG AG                               | 760 |
| 40 |   |     |

23. Un polypeptide comprenant une séquence de polypeptide qui est pour au moins à 90% identique à un polypeptide comprenant la séquence suivante d'aminoacides :

45

50

55

Gln Gly Ile Cys Arg Asn Arg  
1 5

5 Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro  
10 15 20

Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu  
10 25 30 35

15 Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser  
40 45 50 55

Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser  
15 60 65 70

Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val  
20 75 80 85

Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys  
25 90 95 100

Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe  
105 110 115

Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys  
120 125 130 135

30 Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser  
140 145 150

Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser  
35 155 160 165

Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala  
170 175 180

40 24. Le polypeptide de la revendication 23 comprenant les aminoacides suivants:

Gln Gly Ile Cys Arg Asn Arg  
1 5

45 Val Thr Asp Asp Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro  
10 15 20

50

55

Lys Asp Tyr Lys Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu  
 25 30 35  
 5 Pro Ser His Cys Trp Ile Ser Glu Met Val Glu Gln Leu Ser Val Ser  
 40 45 50 55  
 Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser  
 10 60 65 70  
 Asn Tyr Ser Ile Ile Asp Lys Leu Val Lys Ile Val Asp Asp Leu Val  
 15 75 80 85  
 15 Glu Cys Met Glu Glu His Ser Phe Glu Asn Val Arg Lys Ser Ser Lys  
 90 95 100  
 Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Lys Phe Phe Gly Ile Phe  
 20 105 110 115  
 20 Asn Arg Ser Ile Asp Ala Phe Lys Asp Leu Glu Met Val Ala Pro Lys  
 120 125 130 135  
 Thr Ser Glu Cys Val Ile Ser Ser Thr Leu Thr Pro Glu Lys Asp Ser  
 25 140 145 150  
 Arg Val Ser Val Thr Lys Pro Phe Met Leu Pro Pro Val Ala Ala Ser  
 155 160 165  
 30 Ser Leu Arg Asn Asp Ser Ser Ser Asn Arg Lys Ala  
 170 175 180

25. Un polypeptide comprenant une séquence de polypeptide qui est pour au moins à 90% identique à un polypeptide  
 35 comprenant la séquence suivante d'aminoacides :

Ala Pro Thr Arg Pro Pro Ser Pro  
 1 5  
 40 Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser  
 10 15 20  
 Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val  
 45 25 30 35 40  
 Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln  
 45 50 55  
 50 Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg  
 60 65 70  
 Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys  
 55 75 80 85

5 Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys  
 90 95 100  
 Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp  
 105 110 115 120  
 Cys Trp Gly Pro Val Lys Lys  
 10 125

26. Le polypeptide de la revendication 25 comprenant les aminoacides suivants:

15 Ala Pro Thr Arg Pro Pro Ser Pro  
 1 5  
 Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser  
 20 10 15 20  
 Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val  
 25 25 30 35 40  
 Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln  
 25 45 50 55  
 Thr Arg Leu Asn Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Arg  
 30 60 65 70  
 Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys  
 75 80 85  
 Pro Leu Thr Glu Glu Thr Ser Cys Glu Thr Gln Ser Ile Thr Phe Lys  
 35 90 95 100  
 Ser Phe Lys Asp Ser Leu Asn Lys Phe Leu Phe Thr Ile Pro Phe Asp  
 105 110 115 120  
 Cys Trp Gly Pro Val Lys Lys  
 40 125

27. Un polypeptide comprenant une séquence qui est pour au moins à 90% identique à un polypeptide comprenant la séquence suivante d'aminoacides :

45 Met Pro Thr  
 1  
 Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Gln Glu Ile Thr  
 50 5 10 15  
 Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu  
 55 20 25 30 35

Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu  
 40 45 50  
 5 Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly  
 55 60 65  
 Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met  
 10 70 75 80  
 Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe  
 85 90 95  
 15 Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys  
 100 105 110 115  
 Pro Met Ile Thr Glu Pro  
 20 120

28. Le polypeptide de la revendication 27 comprenant les aminoacides suivants:

25 Met Pro Thr  
 1  
 Thr Thr Leu Gin Pro Lys Asn Tyr Leu Ala Met Ile Gin Glu Ile Thr  
 5 10 15  
 30 Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu  
 20 25 30 35  
 Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu  
 35 40 45 50  
 Glu Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly  
 55 60 65  
 40 Ile Lys Lys Asn Leu Glu Lys Phe Arg Pro Ile Leu Pro Thr Ser Met  
 70 75 80  
 Ser Thr Glu Glu Pro Ile Ser Ile Glu Glu Gly Asp Leu Gly Asp Phe  
 45 85 90 95  
 Arg Ala Lys Leu Met Glu Tyr Leu Val Val Leu Arg Asp Ser Leu Lys  
 100 105 110 115  
 Pro Met Ile Thr Glu Pro  
 50 120

29. Application de l'un ou plusieurs des polypeptides selon l'une quelconque des revendications 23 à 28, à la préparation d'une composition destinée à favoriser la greffe de cellules de moelle osseuse porcine sur un récepteur xénogène.

30. Application de l'un ou plusieurs des poly-nucléotides selon l'une quelconque des revendications 1 à 10, à la préparation d'une composition destinée à favoriser la greffe de cellules de moelle osseuse porcine sur un récepteur

xénogène.

**5**

**10**

**15**

**20**

**25**

**30**



**35**

**40**

**45**

**50**

**55**



## CHEF - 3 SEQUENCE

## FIG. 3A

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ATG | AAG | AAC | CAA | ACT | TGG | ATT | ATC | ACT | TGC | ATT | TAT | CTT | CAA | CTG | 63  |     |
| Met | Lys | Lys | Thr | Gln | Thr | Trp | Ile | Thr | Cys | Ile | Tyr | Leu | Gln | Leu | -10 |     |
| -25 |     |     |     |     |     |     |     |     |     |     |     |     |     |     | -15 |     |
| CTC | CTA | TTT | AAT | CCT | CTC | GTC | AGA | ACT | CAA | GGG | ATC | TGC | AGG | AAC | CGT | 111 |
| Leu | Leu | Phe | Asn | Pro | Leu | Val | Arg | Thr | Gln | Gly | Ile | Cys | Arg | Asn | Arg | 5   |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 1   |     |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | -5  |     |
| GTG | ACT | GAT | GAT | GTG | AAA | GAC | GTT | ACA | AAA | TTG | GTG | GCA | AAT | CTT | CCA | 159 |
| Val | Thr | Asp | Asp | Val | Lys | Asp | Val | Thr | Lys | Leu | Val | Ala | Asn | Leu | Pro |     |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 20  |     |
| AAA | GAC | TAT | AAG | ATA | ACC | CTC | AAA | TAT | GTC | CCC | GGG | ATG | GAC | GTT | TTG | 207 |
| Lys | Asp | Tyr | Lys | Ile | Ile | Thr | Leu | Lys | Tyr | Val | Pro | Gly | Met | Asp | Val | Leu |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 35  |     |
| CCT | AGT | CAT | TGT | TGG | ATA | AGC | GAA | ATG | GTG | GAA | CAA | CTG | TCA | GTC | AGC | 255 |
| Pro | Ser | His | CYS | Trp | Ile | Ser | Glu | Met | Val | Glu | Gln | Leu | Ser | Val | Ser |     |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 50  |     |
| TTG | ACT | GAT | CTT | CTG | GAC | AAG | TTT | TCC | AAT | ATT | TCT | GAA | GGC | TTG | AGT | 303 |
| Leu | Thr | Asp | Leu | Leu | Asp | Lys | Phe | Ser | Asn | Ile | Ser | Glu | Gly | Leu | Ser |     |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 65  |     |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 70  |     |

MATCH WITH FIG. 3B

## MATCH WITH FIG. 3A

## FIG. 3B

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| AAT | TAT | TCT | ATC | ATA | GAC | AAA | CTT | GTG | AAA | ATT | GTT | GAT | GAC | CTC | GTG | 351 |
| Asn | Tyr | Ser | Ile | Ile | Asp | Lys | Leu | Val | Lys | Ile | Val | Asp | Asp | Leu | Val | 85  |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| GAA | TGC | ATG | GAA | GAA | CAC | TCA | TTT | GAG | AAT | GTA | AGA | AAA | TCA | TCT | AAG | 399 |
| Glu | Cys | Met | Glu | Glu | His | Ser | Phe | Glu | Asn | Val | Arg | Lys | Ser | Ser | Lys | 90  |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| AGC | CCA | GAA | CCC | AGG | CTG | TTT | ACT | CCT | GAA | AAA | TTC | TTT | GGG | ATT | TTT | 447 |
| Ser | Pro | Glu | Pro | Arg | Leu | Phe | Thr | Pro | Glu | Lys | Phe | Phe | Gly | Ile | Phe | 105 |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| AAT | AGA | TCC | ATC | GAT | GCC | TTC | AAG | GAT | TTG | GAG | ATG | GTG | GCA | CCT | AAA | 495 |
| Asn | Arg | Ser | Ile | Asp | Ala | Phe | Lys | Asp | Leu | Glu | Met | Val | Ala | Pro | Lys | 120 |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| ACT | AGT | GAA | TGT | GTG | ATT | TCT | TCA | ACA | TTA | ACT | CCT | GAA | AAA | GAT | TCC | 543 |
| Thr | Ser | Glu | Cys | Val | Ile | Ser | Ser | Thr | Leu | Thr | Pro | Glu | Lys | Asp | Ser | 140 |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| AGA | GTC | AGT | GTC | ACA | AAA | CCA | TTT | ATG | TTA | CCC | CCT | GTT | GCA | GCC | AGC | 591 |
| Arg | Val | Ser | Val | Thr | Lys | Pro | Phe | Met | Leu | Pro | Pro | Val | Ala | Ala | Ser | 155 |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| TCC | CTT | AGG | AAT | GAC | AGC | AGT | AGC | AGT | AAT | AGG | AAA | GCC | TAA |     |     | 633 |
| Ser | Leu | Arg | Asn | Asp | Ser | Ser | Ser | Ser | Asn | Arg | Lys | Ala |     |     |     | 170 |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |







FIG. 4





## CHEF-2 SEQUENCE

## FIG. 8 A

GGCCGGCTAA AGGCTAAAGT CCTCAGAAGG ATG TGG CTG CAG AAC CTC CTT CTC CTG 56  
 Met Trp Leu Gln Asn Leu Leu Leu Leu -10  
 -15

GGC ACT GTC GTC TGC AGC ATC TCC GCT CCC ACC CGC CCA CCC AGC CCT 104  
 Gly Thr Val Val Cys Ser Ile Ser Ala Pro Thr Arg Pro Pro Ser Pro 5  
 -5

GTC ACC CGG CCC TGG CAG CAT GTC GAT GCC ATC AAA GAA GCC CTC AGC 152  
 Val Thr Arg Pro Trp Gln His Val Asp Ala Ile Lys Glu Ala Leu Ser 20  
 10

CTT CTA AAC AAC AGT AAT GAC ACA GCG GCT GTG ATG AAT GAA ACC GTA 200  
 Leu Leu Asn Asn Ser Asn Asp Thr Ala Ala Val Met Asn Glu Thr Val 35  
 25

GAC GTC TGT GAA ATG TTT GAC CCC CAG GAG CCG ACA TGC TGT CAG 248.  
 Asp Val Val Cys Glu Met Phe Asp Pro Gln Glu Pro Thr Cys Val Gln 50  
 45

ACT CGC CTG AAC CTG TAC AAG CAG GCC CTG CGG GCC AGC CTC ACT AGC 296  
 Thr Arg Leu Asn Leu Tyr Lys Gln Gln Leu Arg Gly Ser Leu Thr Arg 65  
 60

CTC AAG AGC CCC TTG ACT CTG TTG GCC AAG CAC TAT GAG CAG CAC TGC 344  
 Leu Lys Ser Pro Leu Thr Leu Leu Ala Lys His Tyr Glu Gln His Cys 85  
 75

MATCH WITH FIG. 8 B

MATCH WITH FIG. 8A

FIG. 8B

|             |            |            |             |            |                   |     |     |             |            |            |     |     |     |             |     |     |
|-------------|------------|------------|-------------|------------|-------------------|-----|-----|-------------|------------|------------|-----|-----|-----|-------------|-----|-----|
| CCC         | CTC        | ACC        | GAG         | GAA        | ACT               | TCC | TGT | GAA         | ACC        | CAG        | TCT | ATC | ACC | TTC         | AAA | 392 |
| Pro         | Leu        | Thr        | Glu         | Glu        | Glu               | Thr | Ser | Cys         | Glu        | Thr        | Gln | Ser | Ile | Thr         | Phe | Lys |
| 90          |            |            |             |            |                   |     |     |             |            |            |     |     |     |             |     | 100 |
| AGT         | TTC        | AAA        | GAC         | AGT        | CTG               | AAC | AAA | TTT         | CTT        | TTT        | ACC | ATC | CCC | TTT         | GAC | 440 |
| Ser         | Phe        | Lys        | Asp         | Ser        | Leu               | Asn | Lys | Phe         | Leu        | Phe        | Thr | Ile | Pro | Phe         | Asp |     |
| 105         |            |            |             |            |                   |     |     |             |            |            |     |     |     |             |     | 120 |
| TGC         | TGG        | GGG        | CCA         | GTC        | AAA               | AAG | TAA | AGCAGCCTGCG | AGCAGCCAGA | AGCAGCCCTT |     |     |     |             |     | 494 |
| Cys         | Trp        | Gly        | Pro         | Val        | Lys               | Lys |     |             |            |            |     |     |     |             |     |     |
|             |            |            |             |            |                   |     |     |             |            |            |     |     |     |             |     | 125 |
| GGCGCACCGGA | TGGCTCCAC  | TGACAGAGCC | AAACCAAACCT | CAGGATCTC  | ACCGTGGAGG        |     |     |             |            |            |     |     |     |             |     | 554 |
| GACCACTGGC  | TGGCCAAGGC | TGTAACTGGG | CACAGACTTG  | CCCTGGGCCA | TGTTGACCCCT       |     |     |             |            |            |     |     |     |             |     | 614 |
| GATACAGGCC  | TGGCAGGGGA | AATGGCAGAT | GTTTTATACC  | GGCAGGGATT | AGCAATATT         |     |     |             |            |            |     |     |     |             |     | 674 |
| ATTAACCTAT  | TTATGTATT  | TAATATTAT  | ATCTATTAT   | TTATTAAAGC |                   |     |     |             |            |            |     |     |     |             |     | 734 |
| TTGAACCTCA  | TATTATTCA  | AGATGTTTA  | CCATAATAAT  | AAATTATTA  | <u>AAATAGCGGC</u> |     |     |             |            |            |     |     |     |             |     | 794 |
|             |            |            |             |            |                   |     |     |             |            |            |     |     |     | <u>CGCT</u> | 798 |     |




FIG. 9

FIG. 10

■ pGM-CSF  
■ MOCK - CM

DAY 3 PROLIFERATION OF FRACTION 3  
(PIG # 10758)  
IN CHEF 2




FIG. 11





FIG. 13



## CHEF-I SEQUENCE

## FIG. 12A

|   |   |    |
|---|---|----|
| <u>GGA TCCATCGTAC CGGCCAAC</u>                                      | ATG AGC AGC CTC CCC CTT ATG CAT CTG CTC | 53 |
| Met Ser Ser Leu Pro Leu Met His Leu Leu                             |   |    |
|   | -20                                     |    |
| CTG CTG CTC ACA CTC CAT CCT CCT CAG GCA CAG GGG ATG CCT ACC         | 101                                     |    |
| Leu Leu Leu Leu Thr Leu His Ala Pro Gln Ala Gln Gly Met Pro Thr     |   |    |
|   | -5                                      |    |
|   | 1                                       |    |
| ACA ACA CTC CAA CCT AAA AAC TAC CTT GCC ATG ATC CAG GAA ATT ACA     | 149                                     |    |
| Thr Thr Leu Gln Pro Lys Asn Tyr Leu Ala Met Ile Glu Ile Thr         |   |    |
|   | 5                                       |    |
|   | 10                                      |    |
| AGA AGC CTA GAG AAC CTA ACT GTG ACT TCA AAT AAA TCC TTG ACG TTG     | 197                                     |    |
| Arg Ser Leu Glu Asn Leu Thr Val Thr Ser Asn Lys Ser Leu Thr Leu     |   |    |
|   | 20                                      |    |
|   | 25                                      |    |
| AAT GAG CTC GAA ACC CTG GTG AAT AAC ACT CTT CTG AGA CCA AAC CTG     | 245                                     |    |
| Asn Glu Leu Glu Thr Leu Val Asn Asn Thr Leu Leu Arg Pro Asn Leu     |   |    |
|   | 40                                      |    |
|   | 45                                      |    |
| GAA GCA TTC GTG ACA TTT GCT GAA AAC CAC TTA AAA AAT ATT TCA GGA     | 293                                     |    |
| Glu Ala Ala Phe Val Thr Phe Ala Glu Asn His Leu Lys Asn Ile Ser Gly |   |    |
|   | 55                                      |    |
|   | 60                                      |    |
|   | 65                                      |    |

MATCH WITH FIG. 12B

## MATCH WITH FIG. 12A

## FIG. 12B

|            |             |              |             |             |            |     |            |            |            |     |     |     |     |     |     |     |
|------------|-------------|--------------|-------------|-------------|------------|-----|------------|------------|------------|-----|-----|-----|-----|-----|-----|-----|
| ATC        | AAG         | AAA          | AAC         | CTT         | GAG        | AAA | TTC        | CGG        | CCA        | ATC | CTG | CCC | ACG | TCT | ATG | 341 |
| Ile        | Lys         | Lys          | Asn         | Leu         | Glu        | Lys | Phe        | Arg        | Pro        | Ile | Leu | Pro | Thr | Ser | Met |     |
|            |             |              |             |             |            |     |            |            |            |     |     |     |     |     |     | 80  |
|            |             |              |             |             |            |     |            |            |            |     |     |     |     |     |     | 75  |
| TCC        | ACG         | GAA          | GAG         | CCA         | ATC        | TCT | ATT        | GAG        | GAG        | GGC | GAC | CTT | GGT | GAT | TTC | 389 |
| Ser        | Thr         | Glu          | Glu         | Pro         | Ile        | Ser | Ile        | Glu        | Glu        | Gly | Asp | Leu | Gly | Asp | Phe |     |
|            |             |              |             |             |            |     |            |            |            |     |     |     |     |     |     | 95  |
| CGG        | GCG         | AAA          | CTG         | ATG         | GAG        | TAT | CTG        | GTT        | GTC        | CTT | AGA | GAC | TCT | CTG | AAA | 437 |
| Arg        | Ala         | Lys          | Leu         | Met         | Glu        | Tyr | Leu        | Val        | Val        | Val | Leu | Arg | Asp | Ser | Leu | Lys |
|            |             |              |             |             |            |     |            |            |            |     |     |     |     |     |     | 110 |
| 100        |             |              |             |             |            |     |            |            |            |     |     |     |     |     |     | 115 |
| CCC        | ATG         | ATC          | ACA         | GAG         | CCC        | TAA | AATCTGAAGT | GTGAACTCCA | GCTCTCTCTC |     |     |     |     |     |     | 488 |
| Pro        | Met         | Ile          | Thr         | Glu         | Pro        |     |            |            |            |     |     |     |     |     |     |     |
|            |             |              |             |             |            |     |            |            |            |     |     |     |     |     |     | 120 |
| TGGAGCCCTG | GAACGTCAGG  | AACACCGAGT   | CGTCCCTAAGA | TGCGGTGGACC | GTCTCTCACA |     |            |            |            |     |     |     |     |     |     | 546 |
| CCATCCAGGA | CTGACGTTT   | CTCCCTGTTGAA | GTCTGTGAA   | TTGTTAACTA  | TCTAATCCCT |     |            |            |            |     |     |     |     |     |     | 608 |
| GAAATGTCGA | GCCCCATTG   | TCCTTTGCG    | ATTAGGTCT   | CATTTTATT   | GTATTGAGGC |     |            |            |            |     |     |     |     |     |     | 668 |
| TATTATTTA  | TGTATGTATT  | TATTATTTAT   | CTTGTGCAAT  | GTGAAATGTA  | TTTACTTAAC |     |            |            |            |     |     |     |     |     |     | 728 |
| AGAGAAGCCA | TGGCCCTGCTC | CTTCTGAAATG  | AG          | 760         |            |     |            |            |            |     |     |     |     |     |     |     |

FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 22 A




FIG. 22 B




FIG. 22C




FIG. 22D




FIG. 23A





FIG. 23B



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**